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ABSTRACT
The clinical use of methylphenidate for pre-school 
aged children has become increasingly common over the last
decade., However, little is known about the long-term
effects of stimulant medication on this age group.
Developmental studies in rodents suggest that early
methylphenidate exposure, may alter later reward to drugs of
abuse and cause alterations in neuronal functioning. These
studies have generated conflicting results, with some
studies suggesting that methylphenidate decreases later
drug reward while other studies indicating methylphenidate
increases later drug reward. The present study examined
the effect of preweanling methylphenidate exposure on later
drug reward. To this end, we examined the induction,
extinction, and reinstatement of morphine-induced
conditioned place preference (CPP) in rats that received
methylphenidate pretreatment during the preweanling period.
It was predicted that rats pretreated with methylphenidate
would show a greater preference for morphine. In addition,
methylphenidate pretreated rats were predicted to
extinguish more slowly and show a greater morphine-induced
CPP after reinstatement. The results of our study indicate
that preweanling methylphenidate exposure does affect
iii
morphine CPP. While methylphenidate pretreated rats did
not show an initial preference for morphine, the other two
predictions were supported. Rats pretreated with the high
dose of methylphenidate were slower to extinguish as
compared to rats pretreated with the low dose of
methylphenidate or saline. In addition, CPP was more
easily reinstated in rats pretreated with the high dose of
methylphenidate than rats pretreated with the low dose of
methylphenidate or saline. These findings have
implications for the use of methylphenidate in pre-school
aged children as a risk factor for vulnerability towards
drug abuse. Our findings indicate that early
methylphenidate exposure increases later drug reward,
therefore increasing vulnerability towards drug abuse. One
may be more susceptible towards drug addiction because
drugs of abuse become more rewarding following stimulant
treatment in early childhood.
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CHAPTER ONE
STIMULANT MEDICATION IN
EARLY DEVELOPMENT
Attention-Deficit/
Hyperactivity Disorder
Attention-deficit hyperactivity disorder (ADHD) is the
most common neuropsychiatric diagnosis given to children,
with currently 3% - 5% of children meeting the DSM-IV
diagnostic criteria for the disorder (Kwasman, Tinsley &
Lepper, 1995) . The disorder disrupts central nervous system 
regulation of attention span, impulsiveness, and motor 
activity, and presents significant challenges to affected
children, their families, and the school system (Kwasman et
al., 1995). Given the high prevalence of this problem,
along with its major impact on quality of life, it is 
imperative that we study its possible etiologies, clinical
manifestations, and treatments (Palfrey, Levine, Walker &
Sullivan, 1985).
Stimulant Medication to 
Treat Attention-Deficit/
Hyperactivity Disorder
Outpatient visits devoted to ADHD increased from 1.6
to 4.2 million per year during the years of 1990-1993
1
(Swanson, Lerner & Williams, 1995) . During those visits,
90% of the children were given prescriptions, 71% of which
were for the stimulant, methylphenidate. Methylphenidate
production in the United States increased from 1,784 kg to
5,110 kg during the same time period, so that over 10
million prescriptions for methylphenidate were written in
1996 (Vitiello & Jensen, 1997).
Stimulant medication remains the most common way to
treat ADHD. One study surveyed randomly selected members
of the American Academy of Pediatrics (AAP) concerning ADHD
assessment and treatment (Copeland, Wolraich, Lindgren,
Millch & Woolson, 1987). The respondents in the survey
reported that their most frequently used therapy for ADHD
was methylphenidate. In a follow up to this study,
children, physicians, parents and teachers were intensively
interviewed in an effort to ascertain the treatment used
for children with ADHD (Wolraich et al., 1990). Findings
from this study indicated that stimulant medication,
particularly methylphenidate, was the treatment of choice
for ADHD by family practice physicians. More recently, in
a national survey of 380 members of the American Academy of
Pediatrics, respondents reported that 50% of their patients
had not received educational testing before they wrote
2
prescriptions for methylphenidate and similar drugs, and 
even fewer of their patients received psychological testing
(Kwasman et al., 1995). In terms of medications that the
pediatricians reported using in treating ADHD,
methylphenidate was reported as being prescribed 97.6% of
the time (Kwasman et al., 1995). Finally, in the only
study that used a nationally representative sample of 
patient records from office-based physicians, it was found
that over 26% of the children receiving psychotropic
medications were not scheduled for follow-up visits and
only 36% were provided any counseling or psychotherapy
(Kelleher, Hohmann & Larson, 1989). The 1996 Practice
Parameters for the Assessment and Treatment of Children,
Adolescents, and Adults with ADHD cite three "cornerstones"
of treatment: parent support and education, appropriate
school placement, and pharmacology. However, as evidenced
in the research, it appears that stimulant medication is
the predominant and preferred method of treatment for ADHD,
to the extent that other treatment modalities have been
neglected. Because stimulant medication is prescribed so
readily for ADHD, it is important that the possible
aversive long-term consequences be examined.
3
Stimulant Medication 
■ Effectiveness
Although there are few long-term studies, stimulant
medication has been proven effective in reducing ADHD
symptoms. Stimulants improve disruptive ADHD behaviors in
the home, classroom, and playground (Solanto, Arnsten &
Castellanos, 2001). At home, stimulants improve compliance
and parent-child interactions (Whalen et al., 1989). In
the classroom, stimulants increase on-task behavior and
decrease interrupting and restlessness (Abikoff &
Gittelman, 1985). On the playground, stimulants reduce
covert aggression (Hinshaw, Heller & McHale, 1992), overt
aggression (Gadow, Nolan, Sverd, Sprafkin & Paolicelli,
1990), and symptoms of conduct disorder (Klein et al.,
1997) and increase attention during sports (Pelham et al.,
1990). Stimulants decrease impulsive responding and
response variability on cognitive tasks (Tannock, Schachar
& Logan, 1995); increase accuracy of performance, improve
sustained attention, short-term memory, and reaction time
(Hinshaw, Henker, Whalen, Ehrardy & Dunnington, 1989). In
addition to treating ADHD symptoms, stimulant medications
are beneficial in treating other medical conditions, such
as narcolepsy and depression (Goldman, Genei, Bazman &
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Stanetz, 1998). Because stimulant medication is so
successful in reducing ADHD symptoms, it is understandable
why physicians use it as the predominant way to treat ADHD.
The general consensus in the medical community is that the
effectiveness of stimulant medication in treating ADHD
outweighs its side effects. However, because the possible
long-term aversive effects have not been studied
thoroughly, it is important that research continue to
examine this possibility. One major concern is whether
stimulant treatment produces neurotoxic effects that would
later increase vulnerability towards drugs of abuse.
Preschool-Aged Children 
and Attention-Deficit/
Hyperactivity Disorder
The signs and symptoms of ADHD are now believed to be
evident before the age of 3 (Solanto et al., 2001). Even
though ADHD-related behaviors displayed by preschool age
children resemble behaviors among older ADHD patients, the
diagnostic manuals give little guidance about the validity
of ADHD diagnosis in the preschool years. School-age norms
gathered on standard teacher global rating forms, such as
the Conners Teacher Questionnaire (CTQ), have not included
preschoolers until recently (Solanto et al., 2001). For
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many reasons, the clinical diagnosis of ADHD in preschool
children is challenging. The first problem in diagnosis is
the nonspecificity of ADHD symptoms in the 2- to 5-year old
range. The core symptoms of ADHD - inattention,
impulsivity, and overactivity are common daily behaviors of
most preschool aged children. Studies have shown that up
to 40% of children by the age of 4 years have enough
problems with inattention to cause concern to their parents
and preschool teachers (Palfrey et al., 1985). Yet studies
also show that the vast majority of these concerns are
short-lived and generally diminish within 3 to 6 months.
Even among those children whose symptoms are .severe and
frequent enough to justify a diagnosis of ADHD in the
preschool years, only 48% will have the same diagnosis by
later childhood or adolescence. These findings suggest
that the appearance of significantly inattentive or
overactive behaviors by age 3 to 4 years, by themselves, is
not indicative of a persistent pattern of ADHD in later
childhood or adolescence in at least 50% of preschool
children (Barkley, 1998). However, there are those
preschool age children who do display ADHD symptoms and do
warrant the diagnosis and treatment for ADHD.
Approximately 5% to 10% of preschoolers with parental or
6
teacher concerns about inattention eventually develop a
pattern of persistent inattention consistent with ADHD by
the second grade (Palfrey et al., 1985). One study
characterized a sample of preschool aged children as either
'true' hyperactive or 'situationally' hyperactive
(Campbell, Endman & Bernfield, 1977). 'True' hyperactive
children were characterized by cross-situational high
activity while 'situationally' hyperactive children were
those who were situation-specific hyperactive, with their
hyperactivity being observed only in the home. They found
that children classified as 'true' hyperactive in the
preschool years continued to manifest problems in
elementary school as measured by classroom observation and
teacher ratings. In assessing preschoolers who display
significant attentional or behavioral difficulties, the
clinical task is to distinguish between the 5% to 10% who
will develop ADHD and the 90% to 95% who have
developmentally appropriate and temporary symptoms of ADHD-
like symptoms from other causes. Thus, the degree of ADHD
symptoms, their pervasiveness across settings, and their
duration determine which children with early-onset
difficulties are likely to show a chronic course of their
ADHD symptoms throughout development (Barkley, 1998).
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Preschool-Aged Children 
and Stimulant Medication
Although research has indicated that diagnosing ADHD
in the early years is difficult, the clinical use of
stimulant medication for 3- to 6- year old preschool
children who meet the diagnostic criteria for ADHD is
becoming more common. There is a growing concern about the
increasing numbers of young children being treated with
stimulants (Safer & Zito, 1996). Unfortunately, there is a
lack of research.assessing stimulant effects on the very
young and developing brain.
Since 1975, only nine double-blind placebo-controlled
studies have assessed the efficacy of stimulants for ADHD
in preschool children 1.8 to 6 years of age (Connor, 2002).
All nine studies assessed ADHD children on methylphenidate.
No other type of stimulant (Adderall, Concerta,
dextroamphetamine, or pemoline) has been assessed under
controlled conditions in the preschool age range. Studies
have assessed the efficacy of methylphenidate in
alleviating ADHD symptoms by using reports from parents,
caregivers, and nursery school personnel. Only one
controlled study has assessed outcome using laboratory
psychological tests in this age group (Byrne, Bawden,
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DeWolfe & Beattie, 1998). The two neuropsychological
domains assessed in methylphenidate drug studies of 
preschool ADHD children are cognition and attention span.
Behavioral domains assessed include
hyperactivity/impulsivity and interpersonal interactions.
In eight of the nine controlled studies, 89% report
methylphenidate as effective in treating the symptoms of
ADHD in preschool children (Barkley, Karlsson, Strzelecki &
Murphy, 1984; Barkley, 1988; Byrne et al., 1998; Conners,
1975; Cunningham, Siegel & Offord, 1985; Handen, Feldman &
Lurier, 1999; Mayes, Crites, Bixler, Humphrey & Mattison,
1994; Monteiro-Musten, Firestone & Pisterman, 1997). Three
studies report improvements across all domains including
behavioral, interpersonal, and cognitive functioning (Byrne
et al., 1998; Cunningham et al., 1985; Monteiro-Musten et
al., 1997). Improvement is reported in two studies
specifically assessing behavioral domains (Conners, 1975;
Mayes et al., 1994) and in two studies investigating
interpersonal interactions in ADHD preschoolers' (Barkley et
al., 1984; Barkley, 1988).
However, not all methylphenidate studies report
benefits of ADHD children in-the 3- to 6-year old range.
One controlled study found mixed results with many reported
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side effects using methylphenidate in preschool ADHD
children (Schleifer et al., 1975). One study randomly
assigned children to either methylphenidate, cognitive
behavioral therapy, or no treatment. Results did not
demonstrate treatment benefits for either methylphenidate
or behavioral therapy relative to no treatment for 24 ADHD
preschool children (Cohen, Sullivan, Minde, Novak & Helwig
1981). Another controlled study, although reporting
positive effects of drugs on ADHD symptoms in preschoolers,
noted a large variability in individual responses (Conners,
1975). Although not all studies agree, these controlled
studies indicate that methylphenidate in the preschool age
range is beneficial in the treatment of ADHD.
However, there are considerable limitations in the
research literature. The first limitation is the small
number of methodologically controlled studies (nine) and
the small sample sizes of studies assessing stimulant
efficacy for ADHD in the preschool years. Of the 5768
children, adolescents, and adults studied under controlled
conditions in stimulant drug trials for ADHD, only 206
subjects are in the preschool-age range (Spencer et al.,
1996). In order to draw conclusions about the safety and
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efficacy of stimulants for preschool ADHD children, much
more controlled research is necessary.
Also, the duration of methylphenidate drug trials in
the preschool years has been brief. The average length of
methylphenidate therapy in these studies is only a little
longer than 4 weeks. Because ADHD is commonly a chronic
neuropsychiatric disorder that may last several years, and
that preschool ADHD children may be treated with stimulants
for many years, there is a need for studies assessing long­
term stimulant treatment safety and efficacy when stimulant
medication for ADHD is given early in development (Connor,
2002) .
Stimulant Side Effects in 
At tention-Deficit/
Hyperactivity Disorder 
Preschoolers
As the diagnosis of ADHD and use of stimulant
medication become more common in the preschool years, there
is concern about the possible side effects of treating very
young children with these medications. Because studies
done in the 1970's showed many side effects in ADHD
preschoolers treated with methylphenidate, the general
clinical opinion has been that very young ADHD children
experience more frequent and possibly more severe side
11
effects of stimulant medication than older ADHD elementary-
school children (Conners, 1975; Schleifer et al., 1975).
Recently, researchers have begun to systematically
evaluate side effects of stimulant drug treatment in ADHD 
preschoolers in methodologically controlled designs. There 
are two studies presently available (Barkley et al., 1990;
Firestone, Monteiro-Musten, Pisterman, Mercer & Bennett,
1998). These two studies used the same side-effects rating
scales, methylphenidate dosing, and methodological design.
One study assessed methylphenidate side effects on a 17-
item rating scale in school-aged children 5- to 13-years 
old (Barkley et al., 1990). The other study investigated 
methylphenidate on the same 17-item rating scale in
preschool children 4-to 6-years of age (Firestone et al.,
1998) . Doses of methylphenidate used in both studies were
placebo, 0.3 mg/kg and 0.5 mg/kg given twice daily. Both 
studies used a blinded, placebo-controlled crossover design
in which children were randomized to each drug condition
for 7 to 10 days before crossing over into the next drug
condition.
By comparing these two studies, several points about 
methylphenidate side effects can be noted. First, ADHD
children receiving placebo were found to have many of the
12
behavioral side effects attributable to methylphenidate.
Second, methylphenidate side effects in preschool and
school-aged children are generally described as mild.
Third, this comparison of the two studies suggests the
possibility that methylphenidate side effects reported as
severe by parents may be slightly increased in preschool
ADHD children (10%) as compared to older children (3.6%).
Fourth, behaviors reported as side effects may actually
improve on drug treatment (i.e. insomnia, anxiety, and
irritability in ADHD preschoolers). Lastly, except for
appetite suppression, side effects reported as significant
in younger ADHD children (sad, nightmares, drowsy, talks
less, uninterested) are not the same side effects reported
as significant for older school-aged ADHD children
(insomnia, stomachache, headache). This suggests that 
type, frequency, and/or severity of methylphenidate-induced
side effects may change with age and development.
Before conclusions can be made, much more research is
needed that compares safety and efficacy of stimulants
across development. Unanswered questions involve the long­
term safety of stimulant medication for preschool-aged
children and the longer duration of treatment over the
developing years.. It is important to consider the
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possibility of adverse effects of stimulant medication on 
the developing brain. The CNS structures believed to be 
important in the regulation of attention span and motor
activity include the prefrontal cortex, thalamus, basal
ganglia, and cerebellum (Solanto, 1998). Many of these
structures mature well after birth. Thus, stimulant
treatment during early development may alter the
development of these important brain structures. One area
of particular interest is whether early methylphenidate
treatment would alter the brain in such a way as to
increase later vulnerability to drugs of abuse.
Stimulant Treatment as a 
Risk for Substance Abuse
Disorder
It is difficult to investigate within the human
population whether stimulant treatment for ADHD is
associated with adult substance abuse. One reason is that
ADHD, itself, is believed to be a risk factor that
predisposes people to develop alcohol and other drug 
problems (Lynskey & Hall, 2001). Evidence supporting a
role for ADHD in substance abuse comes from studies
reporting elevated rates of childhood ADHD among people
seeking treatment for opiate, cocaine, and other substance
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abuse disorders (Carroll & Rounsaville, 1993). In one
study, 35% of 298 people who sought treatment for cocaine
abuse met the criteria for childhood ADHD (Carroll &
Rounsaville, 1993). Those who reported childhood ADHD were
younger at presentation for treatment and reported earlier 
onset of cocaine abuse, more frequent and intense cocaine
use, higher rates' of alcoholism, and higher rates of 
previous treatment than those who did not report ADHD. In
a longitudinal study, a sample of children referred to
treatment for problems of inattention and hyperactivity
were later assessed at age 18 (Mannuzza, Klein, Bessler,
Malloy & LaPadula, 1998). As part of this study, subjects
with ADHD were compared to a matched control group who did
not meet the criteria for ADHD. Those with ADHD were at a
heightened risk for antisocial personality disorder and
non-alcohol substance abuse disorder.
Another confounding variable in examining the
relationship between stimulant treatment for ADHD and
substance abuse is the co-morbidity between ADHD and other
behavioral disorders. There is a large body of literature
showing a- high degree of correlation between attentional
difficulties and conduct problems (Lynskey & Hall, 2001).
One study reported that nearly 90% of a sample of 128
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clinic-referred children diagnosed with ADHD also met life­
time criteria for co-morbid conduct or oppositional
disorder (Biederman, Wilens, Mick, Spencer & Faraone,
1999). Children who develop conduct disorders are at
heightened risks for a broad range of adverse outcomes in
adolescence and later life, including increased rates of
substance use and substance use-related problems. The
linkages between early attentional difficulties and later
substance use may therefore reflect the associations
between ADHD and conduct disorder and those between conduct
disorder and later substance abuse (Lynskey & Hall, 2001).
Despite the difficulties presented to researchers, a
limited amount of research has investigated the
relationship between stimulant treatment for ADHD and
substance abuse. The research in this area has produced
controversial results (Biederman et al., 1999; Lambert &
Hartsough, 1998; Levin, Evans, McDowell & Kleber, 1998).
Some research suggests that stimulant treatment decreases
the risk of developing a substance abuse disorder while
other research suggests that stimulant treatment increases
the risk of developing a substance abuse disorder. One
study supporting the theory that stimulant treatment
reduces the risk of drug abuse reported that
16
methylphenidate treatment for ADHD not only reduced ADHD
symptoms but also ■ cocaine use in a sample of individuals
with co-morbid ADHD and cocaine dependence (Levin et al.,
1998). Subjects reported reductions in .attention
difficulties, hyperactivity, .and impulsivity. In addition
self-reported cocaine use and craving decreased
significantly. These findings have been supported by
results of a study of substance, abuse in young people with
ADHD (Biederman et al., 1999). In the study, the
cumulative incidence of substance abuse disorders between
medicated subjects with ADHD, non-medicated subjects with
ADHD and children without ADHD were followed-up for a
period of 4 years. Those subjects with ADHD who received
medication were much less likely than non-medicated ADHD
subjects to develop a substance abuse disorder.
Specifically, medication was associated with an 85%
reduction in risk of developing a substance abuse disorder
Additionally, those subjects who received medication were
at approximately the same risk for developing a substance
abuse disorder as the non-ADHD controls..
One study obtained results that support the theory
that stimulant treatment for ADHD increases the risk of
substance abuse (Lambert & Hartsough, 1998). In the study
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subjects were divided into three subgroups. One was 
comprised of ADHD subjects who had received treatment with 
methylphenidate. A second group of subjects had been 
diagnosed with ADHD, but had not received treatment with 
methylphenidate or other CNS stimulants. A third group was 
comprised of age-matched controls who did not have ADHD. 
Frequency of lifetime cocaine use was measured. The
medicated ADHD subjects showed the highest percentage of
cocaine abuse, as indicated by DSM-III-R diagnosis, double
that of either the non-medicated subjects or the age-
matched controls. In addition, the study examined
differential rates of adult smoking among the ADHD subjects
with different stimulant medication histories. It was
found that those ADHD subjects who had used stimulant
medication for a year or more had a significantly higher 
rate of daily smoking than subjects who had no history of
stimulant medication. As evidenced by research using human
subjects, it is still unclear as to whether stimulant
treatment for ADHD increases or decreases the risk of
substance abuse. In addition, interpretation of this
research is challenging since it is difficult to factor out
the variation between the medicated and non-medicated ADHD
subjects. Because of this, it is important that animal
18
studies examining the relationship between stimulant
treatment and substance abuse be conducted.
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CHAPTER TWO
NEUROTOXICITY OF
AMPHETAMINES
Neurotoxic Potential of 
Methylphenidate
Most evidence supports the use of amphetamine-like
stimulants, particularly methylphenidate, as the best
available pharmacotherapy in the treatment of Attention-
deficit hyperactivity disorder (ADHD). While the
therapeutic effects of methylphenidate are well-documented,
little is known about the possible neurotoxic consequences
of exposure to the drug. In particular, the question
remains whether methylphenidate, like other amphetamines,
produces toxic effects on brain monoamine systems.
Methylphenidate acts similarly to other amphetamines in
that it enhances dopaminergic transmission.
Methylphenidate binds to the dopamine transporter and
inhibits dopamine uptake with a potency similar to that of
cocaine (Kuczenski & Segal, 1997). While the toxic
effects of amphetamines have been known for quite some
time, very few studies have examined the neurotoxic
potential of methylphenidate. Those that did evaluate
methylphenidate's potential for neurotoxicity did not find
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that it produced long-lasting changes in brain monoamine
systems (Zaczek, Battaglia, Contrera, Culp & DeSouza, 1989;
Yuan, McCann & Ricaurte, 1997). While the results of these
studies suggest that methylphenidate lacks neurotoxic 
potential, much evidence has been generated regarding the
neurotoxic action of amphetamine and related drugs.
Evidence for Amphetamine 
Neurotoxicity
Studies have revealed several markers of amphetamine-
induced neurotoxicity on dopamine and serotonin systems.
One such marker is a reduction in striatal tyrosine
hydroxylase activity. Tyrosine hydroxylase plays a major
role in the synthesis of dopamine. It is the rate-limiting
enzyme in the production of L-DOPA, the precursor to
dopamine. Methamphetamine administration has been found to
decrease tyrosine hydroxylase activity in rat striatum
(Koda & Gibb, 1973).
In addition to reducing striatal tyrosine hydroxylase,
an abundance of research has shown that amphetamine causes
long-lasting depletions of dopamine and its metabolites in
the striatum (Abekawa, Ohmori & Koyama, 1994; Cass, 1997;
Chapman, Hanson, Kesner & Keefe, 2001; Friedman, Castaneda
& Hodge, 1998; O'Dell, Weihmuller & Marshall, 1991;
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Ricaurte, Guillery, Seiden, Schuster & Moore, 1982;
Ricaurte, Schuster & Seiden, 1980; Robinson, Yew, Paulson &
Camp, 1990). Repeated high doses of methamphetamine have
been found to produce long-term depletions of dopamine in
rat brain (Ricaurete et al., 1980). In addition, repeated
administration of methamphetamine results in marked
decreases in extracellular concentrations of dopamine
metabolites, dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) in rat striatum (Abekawa et al.,
1994; Ricaurte et al., 1982).
Additional evidence demonstrating the neurotoxicity of
amphetamines comes from numerous studies that have shown
that amphetamine reduces number of dopamine uptake sites
(Jonsson & Nwanze, 1982; Nwanze & Jonsson, 1981; Steranka &
Sanders-Bush, 1980; Wagner, Ricaurte, Johanson, Schuster &
Seiden, 1980; Wagner, Ricaurte, Seiden, Schuster, Miller &
Westley, 1980). In one study, the effect of
methamphetamine on number of dopamine uptake sites in the
striatum was examined (Wagner et al., 1980). Results
showed that rats treated with methamphetamine had
significant decreases in total number of dopamine uptake
sites (Vmax) as compared to saline treated rats. The
affinity of residual sites (Km) of methamphetamine treated
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and saline treated rats was not significantly different.
This indicates that reduction in dopamine is caused by a
decrease in dopamine uptake site number and not a decrease
in uptake site affinity. Additional research has shown
that amphetamine, in addition to methamphetamine, produces
a loss of dopamine uptake sites in the striatum (Wagner,
Ricaurte, Johanson et al., 1980). The results of these two
studies suggest that amphetamine and its analogs have toxic
interactions with dopaminergic neurons resulting in long-
lasting alterations of the dopaminergic system. These
results are consistent with the hypothesis that there is
dopamine terminal loss after high doses of methamphetamine
treatment.
In addition to many studies indicating that
amphetamines exert long-lasting neurotoxic effects on 
dopamine neurons, there is also anatomical evidence that
dopamine nerve terminal degeneration follows amphetamine
administration. Degeneration of nerve terminals has been
found in the striatum of methamphetamine-treated rats
(Ricaurte et al., 1982). There was, however, no evidence
that dopamine cell bodies that give rise to these terminals
were destroyed. This indicates that the toxic effect of
methamphetamine is largely, if not exclusively, on dopamine
23
nerve terminals. In another study, to determine if this
terminal degeneration induced by amphetamine was
dopaminergic, the long-lasting dopamine depletion produced 
by methamphetamine was blocked with alpha-methyl-para­
tyrosine (aMPT) (Ricaurte, Seiden & Schuster, 1984). No
evidence of terminal degeneration was found in the striatum
of any of the rats that were administered methamphetamine
in combination with aMPT. The fact that preventing
dopamine synthesis and depleting dopamine blocks
degeneration induced by methamphetamine administration
provides evidence that the degeneration is dopaminergic.
Lastly, methamphetamine treatment has been found to result
in swollen axons in the striatum (Lorenz, 1980). Swollen
axons in the striatum are indicative of increased
neurotransmitter content. Other neurotoxins such as 6-
hydroxydopamine (6-OHDA) also produce swollen, distorted
axons (Malmfors & Sachs, 1968). The present morphological
findings suggest that methamphetamine damages dopamine
nerve terminals selectively in the striatum.
Free Radicals Theory of 
Amphetamine Neurotoxicity
Methamphetamine and amphetamine are selectively
neurotoxic to dopamine and serotonin nerve terminals in the
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central nervous system (Seiden & Sabol, 1996). The
mechanism by which the neurotoxic effect of the amphetamine
analogs occurs has been the subject of research for many
years. Although several mechanisms have been proposed to
explain dopamine-mediated neurotoxicity of amphetamines,
current research supports the role of free radicals. In
this model, it is proposed that amphetamine displaces
dopamine from synaptic vesicles to the cytoplasm, allowing
intraneuronal oxidative stress (Wan et al., 2000). This
occurs because amphetamines cause an increase in dopamine
levels that result in a higher rate of dopamine metabolism.
Dopamine metabolism produces free radicals which are
chemical species that contain unpaired electrons. They are
highly reactive and can cause damage' to nucleic acids,
lipids, and proteins. Once a free radical is formed, it
can react with dopamine to form 6-OHDA, a toxic hydroxy
radical. It is postulated that with large amounts of
dopamine in the synaptic cleft after methamphetamine
treatment, a small proportion of dopamine could be
metabolized to 6-OHDA and transported back into the
dopamine neuron through the dopamine transporter (Seiden &
Sabol, 1996). This model suggests that the formation of
toxic hydroxy radicals from dopamine is the specific
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mechanism by which, amphetamines exert their neurotoxic
effect.
Evidence for the role of free radicals in the
neurotoxicity of amphetamines comes from research showing
that administration of antioxidants such as ascorbic acid
or vitamin E attenuates methamphetamine-induced
neurotoxicity (DeVito & Wagner, 1989; Wagner et al., 1985),
whereas inhibition of the antioxidant, superoxide dismutase
(SOD), by diethyl-dithiocarbamate increases neurotoxicity
(DeVito & Wagner, 1989). Research has shown that there is
a production of superoxide radicals in the striatum of mice
treated with methamphetamine (Cadet, Ladenheim, Baum,
Carlson, and Epstien, 1994; Hirata, Ladenheim, Carlson,
Epstein, and Cadet, 1996). This increase in superoxide
radicals is caused by the release of dopamine after
methamphetamine administration and subsequent dopamine
oxidation within dopamine terminals (Baldwin et al., 1993;
Marshall et al., 1993). Studies such as these have led to
the theory that toxicity of methamphetamine and associated
increase in dopamine oxidation is the result of free
radical formation.
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Dopamine Is Essential for 
Neurotoxicity
Evidence has shown that dopamine is essential for
methamphetamine-induced neurotoxicity (Gibb & Kogan, 1979;
Schmidt, Ritter, Sonsalla, Hanson & Gibb, 1985). When aMPT,
which blocks dopamine synthesis, is administered
concurrently with methamphetamine, it prevents
methamphetamine-induced decreases in tyrosine hydroxylase
activity and on concentrations of dopamine and its
metabolites (Gibb, Johnson & Hanson, -1990) . When dopamine
synthesis was reinstated by concurrent administration of L-
DOPA, a precursor to dopamine, neurotoxicity was again
observed (Gibb & Kogan, 1979).
Additional evidence supporting the role of dopamine in
methamphetamine-induced neurotoxicity comes from research
with dopamine antagonists such as haloperidol and
chlorpromazine. The effect of methamphetamine on both
tyrosine hydroxylase and on concentrations of dopamine and
its metabolites were completely blocked by administration
of chlorpromazine (Buening & Gibb, 1974). These results 
provide evidence that dopamine mediates methamphetamine-
induced neurotoxicity.
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Conclusion
Research has shown that amphetamines produce long-
lasting neurochemical and morphological alterations to the 
dopaminergic system. Because of this, amphetamines are
considered neurotoxic to dopamine nerve cells.
Specifically, amphetamines have been found to exert their
neurotoxic effect by reducing striatal tyrosine hydroxylase
activity, depleting striatal dopamine and its metabolites,
decreasing number of dopamine uptake sites, and resulting
in dopamine nerve terminal degeneration. The dopaminergic
system has been implicated in several important functions,
including movement, attention, learning, and the
reinforcing effects of drugs of abuse (Carlson, 2001) .
Therefore, the neurotoxic effects produced by amphetamines
may disrupt the overall functioning of the dopaminergic 
system. One particular area of interest is whether
amphetamines alter brain neurochemistry to the extent that
drugs of abuse become more rewarding. Furthermore, the
question remains whether amphetamine-induced neurotoxicity
increases vulnerability towards drugs of abuse.
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CHAPTER THREE
DEVELOPMENTAL DIFFERENCES IN
AMPHETAMINE NEUROTOXICITY
Resistance to 
Methamphetamine 
Neurotoxicity in
Young Rats
Methamphetamine administration in adult rats results
in neurotoxicity characterized by reductions of neostriatal
dopamine, tyrosine hydroxylase, and dopamine transporter
sites (Bowyer et al., 1993). In addition to effects on the
dopamine system, methamphetamine administration induces
increases in striatal glial fibrillary acidic protein
(GFAP) in adults (Pu & Vorhees, 1993). .While adult rats
exhibit a characteristic pattern of long-term neurotoxic
effects when administered methamphetamine, developing rats
appear to be resistant to methamphetamine-induced
neurotoxicity (Cappon et al., 1997). Methamphetamine
administered on PND .7-10 or PND 17-20 results in dopamine
reductions only about half as large as those seen in adults
(Lucot, Wagner, Schuster & Lewis, 1982). In addition, it
has been found that there is a transition in susceptibility
to methamphetamine-induced neurotoxicity that occurs around
PND 40 in the rat (Pu & Vorhees, 1993). When examined 3
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days following methamphetamine administration, PND 20 and
PND 40 rats failed to demonstrate decreased tyrosine
hydroxylase immunoreactivity. However, in rats dosed at
PND 60, the normal adult pattern of decreased tyrosine
hydroxylase immunoreactivity was observed. In addition, no
increase in GFAP was found in methamphetamine-treated PND
20 rats, but a small increase was seen at 40 days.
However, a large, adult-typical increase in GFAP was seen
after day 60 of treatment. In another study, the acute and
persistent monoaminergic responses of adolescent (PND 40)
and young adults (PND 90) rats to multiple high doses of
methamphetamine was compared (Kokoshka, Flickenstein,
Wilkins & Hanson, 2000). Results showed that
methamphetamine treatment significantly reduced dopamine 
transporter activity, tyrosine hydroxylase activity, and
dopamine transporter ligand binding in the striatum of PND
90, but not PND 40 animals, to 33-53% of control values 7
days after treatment. These findings confirm previous
findings that adolescent rats (PND 40) do not manifest
long-term deficits in dopamine systems after exposure to
methamphetamine treatment. From these studies, it is 
evident that there are age-dependent differences in the
impact of methamphetamine on the dopamine system.
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Hyperthermia in 
Methamphetamine
Neurotoxicity
The severity of methamphetamine-induced neurotoxicity has
been found to correlate with an accompanying
thermoregulatory response, i.e., a hyperthermic response
facilitates neurotoxicity while a hypothermic response is
neuroprotective (Cappon et al., 1997). Depletion of
striatal dopamine following methamphetamine administration
is linked to a hyperthermic response (Bowyer et al, 1994).
Specifically, decreases in striatal dopamine levels depend.
on the degree of hyperthermia produced during
methamphetamine exposure. In addition, several agents that
block dopamine depletions do so by inhibiting
methamphetamine-induced hyperthermia. Haloperidol,
diazepam, and dizoclipine (MK-801) all reduced
methamphetamine-induced striatal dopamine depletion to a 
degree predicted by their inhibition of hyperthermia.
Also, cold environments that blocked methamphetamine-
induced hyperthermia also blocked methamphetamine
neurotoxicity. In addition, when marked hyperthermia was
produced, it was shown that methamphetamine increased the 
number of astrocytes that contained GFAP immunoreactivity
and silver-degeneration staining in axons and terminals in
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the striatum. From this study/ it can be concluded that
body temperature is a critical determinant of
methamphetamine neurotoxicity.
Hyperthermia in Resistance 
to Methamphetamine
Neurotoxicity 
in Young Rats
A thermoregulatory response has been proposed as a
contributing factor in the resistance to methamphetamine
neurotoxicity in developing rats. The thermoregulatory and
neurotoxic effects of methamphetamine administration in
developing rats at PND 20, PND 40 and PND 60 were
investigated (Cappon, Morford & Vorhees, 1997). Rats at
PND 20 and PND 40 were administered methamphetamine at
ambient temperatures of 22° C and 30° C, and PND 60 rats .
were administered methamphetamine at 22°C only.
Temperatures were measured and thermal responses were
compared by calculating the total thermal response (TTR)
induced by methamphetamine treatment. Results showed that
methamphetamine administration to PND 60 rats at 22°C
induced a hyperthermic response, resulted in a 47%
reduction in neostriatal dopamine and a 49% increase in
GFAP content. Administration of methamphetamine to PND 40
rats at 22°C failed to induce a hyperthermic response and
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did not result in reduced dopamine or increased GFAP.
However, administration of methamphetamine to PND 40 rats
at 30°C induced hyperthermia, reduced neostriatal dopamine
by 54% and increased GFAP by 70%. Methamphetamine
administration to PND 20 rats at either 22° or 30° C did
not result in dopamine depletion or increased GFAP, even
though methamphetamine administration to PND 20 rats at
30°C induced hyperthermia. This study provides evidence
confirming that the transition in neostriatal
susceptibility to methamphetamine occurs at approximately
40 days of age. By contrast, the adult pattern is fully
developed by PND 60. In addition, 20-day-old rats are
resistant to dopaminergic and GFAP effects induced by
methamphetamine treatment.
These findings illustrate the pivotal role of
methamphetamine-induced hyperthermia in the ontogeny of
methamphetamine-induced neurotoxicity (Cappon et al.,
1997). Methamphetamine administered to PND 40 rats at 22°C
failed to induce hyperthermia and did not result in
dopamine depletion or reactive gliosis. This suggests that
PND 40 rats are resistant to methamphetamine-induced
neurotoxicity. However, PND 40 rats treated with
methamphetamine at an ambient temperature of 30°C
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demonstrate hyperthermia, dopamine depletion, and increased
GFAP. Hence, at this age, resistance to methamphetamine-
induced neurotoxicity may be overcome by elevating ambient
temperature to produce hyperthermia. This implies that the
neuroanatomical and/or neurochemical mechanisms underlying
methamphetamine-induced neurotoxicity have developed by PND
40, but the components necessary for methamphetamine to
induce hyperthermia are not yet fully mature. Another
possibility is that PND 40 rats are able to dissipate
excessive heat into the environment better than adults.
PND 20 rats administered methamphetamine at 30°C
demonstrate a hyperthermic response comparable to that seen
in PND 40 animals, yet they are resistant to
methamphetamine-induced reactive gliosis and dopamine
depletions. Consequently, PND 20 rats, unlike PND 40 rats,
are resistant to methamphetamine-induced neurotoxicity
despite induction of hyperthermia. This indicates that the
neuroanatomical and/or neurochemical mechanisms responsible
for methamphetamine-induced neurotoxicity are not present
at PND 20. From this, it can be concluded that
susceptibility to methamphetamine-induced neurotoxicity is 
dependent upon the developmental stage in which it is
administered.
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CHAPTER FOUR
ANIMAL MODELS OF DRUG
REWARD
Introduction
Addiction and drug abuse are significant problems in
the world today. Research on drug abuse and addiction
takes place at many different levels. Within the field of 
neuropsychopharmacology, examination of the neurai
mechanisms of drug reward has become a major area of
research. There are two measures that are most, frequently
used within a laboratory setting to assess the rewarding
properties of drugs., conditioned place preference (CPP) and
drug self-administration. With few exceptions, drugs that
are self-administered have also been found to reliably
produce CPP, and vice versa (Carr, Fibiger & Philips,
1989) .
However, since the e_arly 1980's, there has been some 
disagreement about whether CPP and self-administration
represent two alternative methods for measuring a common
reward process (Bardo & Bevins, 2000). The controversy has
been fueled partly by different views regarding the nature
of reward. Reward has sometimes been equated with the
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subjective experience of pleasure, but science requires
that the concept of reward be related to the organizing
effects that it has on behavior (White, Messier & Carr,
1987). Two major organizing effects of reward have been
identified (Carr et al., 1989). The most prominent effect
is that stimuli which are generally agreed to be rewarding
(incentive stimuli) have the capacity to elicit approach
responses and maintenance of contact with stimuli
(Schneirla, 1959). Another organizing effect of reward is
its capacity to increase the probability that responses
that precede it will be repeated. This strengthening of
the association between environmental stimuli and preceding
response has resulted in this effect being referred to as
'reinforcement' (Skinner, 1938).
Reward Versus Reinforcement
As noted in the behavioral sciences literature, it is
important to remember that reinforcement and reward are two
distinct concepts (White, 1989). Reinforcement is the
process that occurs in the nervous system when contact with
certain stimulus events (called reinforcers) produces a
change in behavior (White et al., 1987). Skinner (1938)
defined a reinforcer as an event that follows a response
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and changes the probability that the response will be
emitted in the future. A stimulus-response association may
be strengthened by reinforcement, but this strengthening
effect does not require that the reinforcer be rewarding or
pleasurable. In fact, a reinforcer has the potential to be
aversive or punishing. In a given environment, the
presence of reinforcing stimuli serves to organize behavior
by orienting the organism towards or against the stimulus
object (Young, 1966). Therefore, reinforcement has come to
refer to the tendency of certain stimuli to strengthen
learned stimulus-response associations (White, 1989).
The notion of reward-has its origin in the writings of
philosophers, who described reward as individuals' natural
tendency to maximize pleasure and minimize pain. This idea
has not changed in any substantial way since it was first
formulated. In modern psychology, the operationalization
of affective states (e.g. reward and aversion), by Young
(1959), provided the model used now for studying these
behavioral processes. According to Young's view, the
operational definition of reward is approach; the
operational definition of aversion is withdrawal. In the
behavioral sciences, reward refers to the fact that certain
environmental stimuli have the property of eliciting
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approach responses and maintenance of contact. The most
common contemporary measures of reward are electrical self­
stimulation or self-administration of drugs, and various
place preference techniques.
Self-Administration 
Paradigm
The self-administration paradigm is a valid and direct
measure of the reinforcing properties of the drug (Koob &
Goeders, 1989). The drug self-administration technique
first requires a surgical procedure whereby a catheter is
inserted into the jugular vein of the animal. This allows
for the intravenous infusion of drug. The animal is then
placed in an operant chamber for self-administration
training and testing. The operant chamber is an enclosed
environment with a small lever on the inside wall. A lever
press will result in an intravenous injection of a drug. A
signal light mounted above the lever can be used to
indicate the onset of injection and remains lit for a
period of time, during which the lever press will no longer
result in drug infusion. Lever-pressing is reinforced
under a schedule of reinforcement (Koob & Goeders, 1989).
Training usually takes place under a fixed ratio (FR1)
schedule of reinforcement. Under a FR1 schedule, every
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lever press results in a drug infusion. Once regular
lever-pressing has been established, the schedule of
reinforcement can be increased. Through the process of
operant conditioning, the animal will learn that drug
infusion is contingent upon pressing the lever. The drug
is considered to be reinforcing if it increases the
probability of the lever-pressing response (Koob & Goeders,
1989). The experimental analysis of biological and
environmental variables which modify the reinforcing
efficacy of the drug, i.e.,, the extent to which a drug is
self-administered, has implications for research on
problems of human drug-seeking behavior, addiction, and
dependence (Koob & Goeders, 1989) .
Conditioned Place 
Preference Paradigm
CPP has been developed as an animal model of drug
reward. To demonstrate CPP, animals are given a drug in
association with distinct environmental cues. A typical
CPP experiment includes differentially pairing two distinct
sets of environmental (contextual) cues with the drug
stimulus. The contextual cues tend to differ along several
stimulus dimensions. The contexts may vary in flooring,
size or shape, wall color or pattern, and olfactory cues.
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Conditioning involves an animal receiving repeated exposure
to the drug stimulus (termed unconditioned stimulus or US)
in one context (termed conditioned stimulus or CS).
Intermixed with these context-drug pairings is similar
exposure to the other context without exposure to the drug
US (Bardo & Bevins, 2000). Following conditioning is a
choice test in which animals receive unrestricted access to
both contexts in the absence of drug (US). Therefore,
during testing, the animal is in a drug-free state. An
increase in time spent in the paired context relative to
time spent in the paired context prior to conditioning is
taken as evidence that the drug (US) is rewarding (Bardo &
Bevins, 2000). Presumably, after receiving pairings of a
drug with a particular environment, an animal that is now
drug-free will spend more time in the drug-paired
environment than in the neutral environment. The increase
in time is attributed to the conditioned reinforcing
properties of environmental stimuli that have previously
been paired with drug (Hoffman, 1989) . The drug is said to
be rewarding because the animal has shown a preference for
the environment paired with drug as opposed to the neutral
environment.
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What Is Learned in 
Conditioned Place
Preference?
CPP is based on principles and operations of classical
(Pavlovian) conditioning. The CPP paradigm is based on the 
assumption that animals will approach rewarding stimuli and 
that neutral stimuli can acquire secondary rewarding 
properties through association with primary rewards (Carr 
et al., 1989). The primary rewarding properties of the 
drug serve as an unconditioned stimulus'that is repeatedly 
paired with a, previously neutral set of environmental
stimuli. The neutral set of environmental stimuli acquire,
in the course of conditioning, secondary rewarding
properties. Having acquired secondary rewarding
properties, they can act as conditioned stimuli which 
elicit approach when the animal is subsequently exposed to 
these stimuli in the absence of drug (Tzschentke, 1998).
Several lines of evidence support the assumption that
CPP involves the acquisition of a reinforcing conditioned 
response (CR) in which reinforcing properties of the drug
become associated with environmental stimuli (Bardo, Miller
& Neisewander, 1984). First, it has been shown that
various drugs may serve as effective primary reinforcers
(Grabowski & Cherek, 1983). Second, environmental stimuli
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which are paired reliably with a drug may elicit a
conditioned response that mimics unconditioned drug
effects. For example, a low dose of morphine produces
hyperthermia, and stimuli associated with this drug effect
can elicit a similar hyperthermic conditioned response
(Miksic, Smith, Numan & Lal, 1975). Third, evidence
indicates that environmental stimuli associated with a
reinforcing drug can direct operant behavior. For example,
rats injected with morphine in association with an
environmental stimulus will perform an operant response
which delivers the environmental stimulus alone (Schuster &
Woods, 1968) .
In CPP, the conditioned response (CR) is not observed
directly, but rather is assumed to be reflected in the
increased time that an animal spends in the presence of
drug-associated stimuli (Bardo et al., 1984). This
assumption is substantiated by research showing that, the
CPP paradigm demonstrates other principles of Pavlovian
conditioning. In Pavlovian conditioning, extinction is a
technique for producing a reduction and eventual
disappearance of the conditioned response (Klein, 2002).
Extinction involves repeatedly presenting the conditioned
stimulus without the unconditioned stimulus (Mazur, 1999).
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The strength of the conditioned response decreases as the
number of CS-alone experiences increases until, eventually,
the conditioned stimulus (CS) elicits no conditioned
response (CR) (Klein, 2002). Research has successfully
demonstrated that the CPP response (CR) can be extinguished
when drug-associated stimuli are presented alone following
conditioning (Mueller, Perdikaris & Stewart, 2002; Mueller
& Stewart, 2000).
Another principle of Pavlovian conditioning that has
been successfully demonstrated using the CPP paradigm is
reinstatement. Reinstatement involves the ability of
conditioned stimuli (CS) to once again elicit a conditioned
response (CR) following extinction. Once a CPP (CR) has
been extinguished, it can be reinstated following a priming
injection of the drug (US) (Parker, & McDonald, 2000; Wang, 
Luo, Zhang & Han, 2000). The extinction / reinstatement
paradigm is often used as a model of relapse to drug use
(Fuchs, Tran-Nguyen, Specio, Groff & Neiswander, 1998).
Comparison Between 
Self-Administration and
Conditioned Place 
Preference
There are three major advantages of drug self­
administration. First, self-administration of a drug by an
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animal is a direct measure of the reinforcing properties of
the drug. The drug increases the probability of a response
and thus acts as a reinforcer. This construct therefore
enables the use of classical operant techniques for the
measurement of motivational values of a drug, allows for
the measure of relative reinforcement value of drugs, and
controls for non-specificity of action of drugs and
assessment of treatment effects (Koob & Goeders, 1989).
Another advantage of drug self-administration is that
clear dose-effect functions can be obtained even in
continuous reinforcement situations, and these dose-effect
functions lend themselves to pharmacological antagonism.
An antagonism results in a shift of the dose-effect
function to the right, which at certain doses, is reflected
in an actual increase in responding for drug. Injection of
an antagonist would produce an increase in the number of
self-injections of drug. This increase is generally
considered to reflect a competitive functional interaction.
The rat presumably increases drug self-administration to
compensate for the decreased effectiveness of the drug as a
reinforcer in the presence of partial receptor occupancy by
the antagonist. Consequently, an increase in self­
administration resulting from administration of a drug
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antagonist is qualitatively similar to the effects of
decreasing the dose of drug per injection (Koob & Goeders,
1989).
The third advantage of self-administration for the
study of drug reinforcement is that this procedure can be
used to study the biological site of action of drugs.
Systemic and local intracerebral injections of
pharmacological antagonists and neurochemically specific
neurotoxins can be combined with these behavioral
procedures to define site and mechanism of action for the
reinforcing properties of drugs (Koob & Goeders, 1989).
There are three main disadvantages of drug self­
administration as measures of the reinforcing properties of
drugs. First, surgery is required that can be difficult in
small rodents. Several particular precautionary procedures
must be used to prevent contamination, and reduce the
problems associated with blood clots and infection (Koob &
Goeders, 198 9).
Secondly, the lever-press response has to be learned,
and time is required for animals to reach stable baselines.
For heroin and cocaine, a 7-to-14-day period is required
for animals to stabilize lever-pressing response (Koob &
Goeders, 1989) .
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The final disadvantage centers on the general non­
specificity of action of drugs. Drugs, rarely, if ever,
have one specific neuropharmacological action, and in the
intravenous technique, drug is delivered throughout the
brain and body. This limits the interpretation of some of
the behavioral preparations, particularly if 'non-
reinforcing' actions are interfering with the ability of
the animal to respond. Intracranial self-administration is
one procedure that can be used to circumvent many of the
non-specific effects associated with systemic drug delivery
(Koob & Goeders, 1989) .
The main advantages of CPP as an animal model of drug
reward are (1) the CPP paradigm allows for either a
preference (CPP) or an aversion (CPA) to be observed after
drug conditioning. Thus, a major benefit in using this
technique is that both rewarding as well as aversive
properties of a drug can be determined using the same
behavioral task; (2) time spent in the environment can be
measured in an animal that is drug-free. Thus, any other
effects of the drug that may coexist with its
rewarding/aversive properties would not directly influence
the time spent in the previously drug-paired environment.
In contrast, using a self-administration paradigm, the
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lever-pressing response is measured while the animal is
under the influence of the drug. Therefore, the
possibility exists that the lever pressing response may be
confounded by the stimulating or sedating effects of the
drug; (3) the CPP preference has been observed with
relatively low doses of drug as compared to self­
administration; (4) the possibility exists that CPP can be
demonstrated in as little as one drug pairing, and when
multiple pairings are used, these pairings can be conducted
either once or twice daily without a decrement in the
associative strength of conditioning. Thus, the relatively
short time necessary for this procedure (i.e., it only
requires 1 or 2 weeks) is an advantage. This contrasts
with self-administration in which repeated self-infusions
of drug are required in order to establish reliable lever­
pressing behavior. This repeated exposure protocol likely
affects receptor transduction mechanisms related to
tolerance and/or sensitization (Bardo & Bevins, 2000); (5)
CPP allows for simultaneous assessment of place preference
and locomotor activity; (6) CPP typically yields dose
effect curves that are monophasic. This contrasts with
self-administration which typically yields a biphasic dose
effect curve; (7) Drugs that have been shown to produce CPP
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are consistently shown to be rewarding/reinforcing in other 
behavioral paradigms. Drugs of abuse are able to produce
CPP and possess reinforcing properties in operant
behavioral tasks (Carr et al., 1989). Thus, predictions
from the CPP task as to the rewarding properties of drugs
are consistent with predictions from other behavioral
paradigms (Schechter & Calcagnetti, 1993).
Despite its numerous advantages, there are some
limitations of CPP as a measure of drug reward. (1) There
are some questions regarding what exactly is being measured
by the CPP paradigm (Schecter & Calcagnetti, 1993). The
possibility exists that animals are not really expressing a
drug-environmental paired preference, but rather are simply
being affected by locomotor activating / sedating actions
of the drug. (2) A major concern regarding CPP is the
potential confounding influence of novelty-seeking behavior
on test day. It is well established that rats prefer a
novel context over a familiar context (Hughes, 1968). This
finding leads to the possibility that pairing drug with one
context retards or blocks complete familiarization to that
context, thus rendering it more novel relative to the
saline context on the drug-free test day (Bardo & Bevins,
2000). One way that researchers have dealt with the issue
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of novelty is to test animals in an apparatus that has
three distinct contexts - one that is novel, one that is
drug-paired, and one that is saline-paired. When tested in
this situation, rats show a preference for the drug-paired
context relative to the novel context (Parker, 1992). (3)
Deficits in performance produced by drug-state dependency
may be considered another limitation of CPP. Animals are
trained in one state in that they experience the drug
effect in a particular environment and they are later
tested in a different state (drug-free). The possibility
exists that the inability to express a preference for the
drug-paired environment is inherent in the fact that
training and testing occur in different subjective states
(Schechter & Calcagnetti, 1993). (4) A final limitation of
CPP is the difficulty in generating the type of dose-effect
relationship normally expected in behavioral pharmacology
(Bardo & Bevins, 2000). In many cases, does-response
relationships have not been observed by varying the dose of
drugs used successfully to produce a CPP. What is often
observed is a "step-up" dose-effect relationship where one
dose does not produce CPP but the next higher dose produces
a positive and maximal effect (Schechter & Calcagnetti,
1993) .
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Are Conditioned Place 
Preference and
Self-Administration 
Comparable Methods for 
Measuring Drug Reward?
There has been conflicting data as to whether CPP and
drug self-administration measure a common reward process.
Partial support for the claim that CPP is similar to self­
administration arises when one compares the ability of each
paradigm to detect reward across various drug classes.
There appears to be reasonable concordance between drugs
that produce CPP and drugs that are self-administered.
Various stimulants, opiates and other drugs are known to
support both CPP and self-administration (Bardo & Bevins,
2000). In contrast, neither CPP nor self-administration is
produced by a host of other drug classes, including
antagonists for dopamine, opioid, and cholinergic
receptors, as well as antidepressants that work on either
noradrenergic or serotonergic systems (Bardo & Bevins,
2000) .
Despite this commonality, there are some significant
exceptions to the general concordance between CPP and self­
administration across drug classes. CPP may be unique in
its ability to detect the rewarding effect of lysergic acid
diethylamide (Meehan & Schecter, 1998), buspirone (Balster,
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1990) , and pentylenetetrazole (Gauvin, Dormer & Holloway,
1991) , whereas self-administration may be unique in its
ability to detect the rewarding effects of pentobarbital
(Collins, Weeks, Cooper, Good & Russell, 1984) and
phencylclidine (Marquis, Webb & Moreton, 1989). This
discordance indicates that CPP and self-administration are
not similar measures of a common reward process (Bardo &
Bevins, 2000) .
In addition to the discrepancy between CPP and self­
administration noted across some drug types, several recent
studies have demonstrated a clear dissociation between CPP
and self-administration. In one study, rats were allowed
to self-administer cocaine for either 6 or 29 sessions.
These two groups were then examined for cocaine CPP, as
well as reinstatement of self-administration using a
cocaine cue (Deroche, Le Moal & Piazza, 1999). Although
the 29-session group self-administered more cocaine than
the 6-session group and showed greater sensitivity to
cocaine's ability to reinstate operant responding, no group
differences in the dose response curve for cocaine CPP were
obtained. These results provide strong evidence that CPP
and self-administration are measuring fundamentally
different processes.
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There are also several examples which indicate that
the neuropharmacological mechanisms that underlie CPP and
self-administration are dissociable. One illustration of
this point comes from studies examining the effects of D2
dopamine antagonists on cocaine CPP and self-administration
in rats. In general, studies have shown that systemic
administration of cocaine induces a CPP that is not altered
by pretreatment injections of various D2 antagonists
administered either systemically (Cervo & Samanin, 1995) or
directly into the nucleus accumbens (Baker, Khroyan,
O'Dell, Fuchs & Neisewander, 1996). This outcome
contrasts with self-administration studies demonstrating
that the reinforcing effect of cocaine is attenuated by D2
antagonists administered either systemically (Ettenberg,
Pettit, Bloom & Koob, 1982) or into the nucleus accumbens
(Phillips, Howes, Whitelaw, Robbins & Everitt, 1994).
Thus, D2 dopamine receptors appear to be involved in the
primary reinforcing effect of cocaine, but not in the
rewarding effect of contextual stimuli paired with cocaine
(Bardo & Bevins, 2000) .
In conclusion, it is apparent that there is
conflicting evidence as to whether CPP and self­
administration are similar measures of drug reward.
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However, the emphasis should not be placed on demonstrating
CPP and self-administration as measures of a common reward
process. Numerous studies have shown both paradigms to be
valid measures of drug reward. CPP and self-administration
uniquely contribute to our understanding of the neural
mechanism underlying drug reward. Further research
utilizing these two animal models of drug reward will
ultimately add to our understanding of drug addiction and
abuse liability.
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CHAPTER FIVE
THE DOPAMINE SYSTEM
AND REWARD
Introduction
The dopaminergic system has been profoundly implicated
in reward mechanisms. It is generally acknowledged that
dopamine receptors in the mesolimbic system mediate the
motivational-affective role of dopamine, while dopamine in
the striatum is responsible for facilitating complex motor
responses (Ikemoto & Panksepp, 1999) . The mesolimbic
system includes the dopamine pathway projecting from the
ventral tegmental area (VTA) to the nucleus accumbens
(Carlson, 2001) . The nucleus accumbens is often cited as a
structure linked with the reward role of dopamine (Stellar,
Keley & Corbett, 1983). The nucleus accumbens can be
divided into two major sub-regions: the shell (ventromedial
part) and the core (dorsolateral part) (Ikemoto & Panksepp,
1999).
Self-Administration Studies
The most convincing evidence that supports the role
of the mesolimbic dopamine system in reward is that animals
self-administer chemicals that mimic dopamine (i.e. direct
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dopamine receptor agonists) or increase extracellular
dopamine (i.e. indirect agonists, e.g., amphetamine)
directly into the nucleus accumbens. In operant
procedures, the response contingent delivery of dopamine
agonists directly into the nucleus accumbens can serve as a
reinforcer for that response (i.e. increase its future
probability of occurrence or strength of association)
(Ikemoto & Panksepp, 1999). Rats self-administer d-
amphetamine within the nucleus accumbens more so than equal
amounts of saline (Hoebel, Monaco, Hernandez, Aulisi,
Stanley & Lenard, 1983). In addition, rats will self-
administer nomifensine, a dopamine reuptake blocker, into
the nucleus accumbens (Carlezon, Devine & Wise, 1995).
These results suggest that response-contingent dopamine
reuptake blockade within the nucleus accumbens is
sufficient to establish and maintain instrumental response
habits. Furthermore, rats acquire and maintain self­
administration of direct dopamine' receptor agonists, a
mixture of SKF 38393 (a Dl-like agonist) and quinpirole (a
D2-like agonist), into the nucleus accumbens (Ikemoto,
Glazier, Murphy & McBride, 1997).
Additional support for the role of dopamine in reward
comes from research on substance abuse. Mammalian species
55
readily acquire and maintain self-administration of
psychostimulants such as amphetamine and cocaine (Schuster 
& Thompson, 1969). Amphetamine and cocaine are known to
stimulate dopamine release and block reuptake in the
nucleus accumbens. The mesoaccumbens dopamine system
appears to play a critical role in mediating reinforcing
effects of these psychostimulants. The role of dopamine in
the reinforcing properties of psychostimulants can best be
exemplified by studies showing that pharmacological
manipulation of the dopamine system can affect self­
administration of these drugs. In one study, dopamine
nerve terminals in the nucleus accumbens were destroyed
with 6-OHDA (Lyness, Friedle & Moore, 1979). It was found
that 6-OHDA injections into the nucleus accumbens abolished
the acquisition of d-amphetamine self-administration. The
results suggest that dopamine neurons in the nucleus
accumbens subserve the activation of a reward system.
Removal of dopaminergic nerve terminals would result in a
failure of indirect agonists like d-amphetamine to produce
a positive (rewarding) stimulus. Therefore, one would 
expect poor acquisition of'self-administration behavior. 
Additionally, in an effort to define the neural circuitry
involved in the reinforcing effects of cocaine, the effect
56
of 6-OHDA-induced lesions of specific catecholamine
pathways and terminal areas on cocaine self-administration 
was examined (Roberts, Koob, Klonoff & Fibiger, 1979).
After cocaine self-administration behavior had stabilized,
the nucleus accumbens was injected with 6-OHDA. When
tested the day following the 6-OHDA injection, rats failed
to self-administer cocaine. However, this disruption did
not resemble extinction. After several days, self­
administration recovered in many animals to near
preoperative levels. The rate of this recovery correlated
with levels of dopamine remaining in the nucleus accumbens.
The animals with the greatest depletion of dopamine did not
recover cocaine intake. The results therefore support the
hypothesis that cocaine interacts with dopaminergic
neuronal mechanisms to produce reinforcement and maintain
self-administration behavior.
Conditioned Place 
Preference Studies
CPP has also been used to demonstrate the role of
dopamine in the rewarding effects of d-amphetamine and 
direct dopamine agonists (Ikemoto & Panksepp, 1999).
Intra-accumbens injections of amphetamine result in a
strong CPP (Carr and White, 1986). The observation of a
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CPP indicates that intra-accumbens injections were
rewarding. Adding the dopamine receptor blocker cis-
flupenthixol to the injection fluid attenuates the CPP
produced by intra-accumbens amphetamine (Ausili & Hoebel,
1983). In addition, systemic injected haloperidol, a
dopamine receptor antagonist, blocks amphetamine-induced
CPP (Phillips, Spyraki & Fibiger, 1982). Dopaminergic
involvement is also implicated by the attenuation of
amphetamine. CPP using selective 6-OHDA lesions of accumbens 
dopamine neurons (Spyraki et al., 1982). These findings
suggest that dopamine release and receptor activation in
the nucleus accumbens are both necessary and sufficient to
produce CPP (White, Packard & Hiroi, 1991).
. ■Brain.Self-Stimulation 
Studies
The brain-stimulation reward paradigm has played a
major role in initiating the idea of dopamine being a
central substrate of brain reward (Lippa, Antelman, Fisher
& Canfield, 1973). Animals readily learn to lever-press
when the lever press results in a brief electrical
stimulation (Olds, 1958). Electrical stimulation to the
medial forebrain bundle, a major pathway interconnecting
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the midbrain and forebrain, has been found to be strongly-
rewarding (Colle & Wise, 1988).
Systematic manipulations of brain dopamine receptors
have marked effects on self-stimulation behavior. The most
compelling evidence suggesting dopaminergic involvement
derives from pharmacological studies. Dopamine agonists
and antagonists, respectively, facilitate and disrupt self­
stimulation behavior (Ikemoto & Panksepp, 1999). The
effect of pimozide, a specific blocker of dopamine
receptors, and amphetamine, a dopamine agonist, on self­
stimulation of the medial forebrain bundle was examined
(Gallistel & Karras, 1983). It was found that pimozide
decreased rate of self-stimulation behavior, thereby
decreasing the rewarding value of brain-stimulation.
Conversely, amphetamine increased rate of self-stimulation,
thereby increasing the rewarding value of brain-
stimulation. Finally, the effect of concurrent
administration of pimozide and amphetamine cancelled each
other out. When administering the combination of pimozide
and amphetamine, rate of self-stimulation was intermediate
to the effects of the two individual treatments. These
results support the hypothesis that pimozide and
amphetamine exert their effects on reward via the same set
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of dopaminergic synapses. In addition, application of
brain stimulation in the VTA increases dopamine levels
within the nucleus accumbens (Blaha & Phillips, 1990).
This finding is consistent with the notion of a
dopaminergic substrate of brain stimulation reward at
electrode sites in the VTA.
Other Drugs of Abuse 
Stimulate Dopamine Release
The potential importance for the role of dopamine in
the rewarding properties of drugs is further highlighted by
findings that many other drugs of abuse, including ethanol,
opioids, cannabis and nicotine, share the ability to
selectively stimulate dopamine release within the
mesolimbic system (Ikemoto & Panksepp, 1999). Intra­
parietal administration of ethanol stimulates dopamine
release and DOPAC and HVA output in the■nucleus accumbens,
and although less, also in the caudate (Imperato & Di
Chiara, 1986). In addition, intravenous administration of
both heroin and delta-9-tetrahydrocannabinol, the active
ingredient in cannabis, increase extracellular dopamine
concentrations in the nucleus accumbens (Tanda, Pontieri &
Di Chiara, 1997). Lastly, nicotine administration results
in an increase in dopamine transmission in the nucleus
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accumbens and caudate (Imperato., Mulas & Di Chiara, 1986) . 
These findings suggest that the reinforcing properties of
these drugs may be mediated by its action on the mesolimbic
dopamine system.
Conclusion
In summary, there is a large body of evidence
supporting the involvement of dopamine in the rewarding
value of stimuli. Behavioral studies such as self-
administration, CPP and electrical brain stimulation all
link dopamine to reward. Also, studies examining drugs of
abuse have shown that dopamine mediates the rewarding
properties of drugs. Additionally, studies have found
dopamine to play a role in the rewarding properties of
natural reinforcers such as food intake (Weingarten &
Watson, 1989), sucrose consumption (Muscat & Willner,
1989), water intake (Gilbert & Cooper, 1987), and
temperature reinforcement (Ettenberg & Carlisle, 1985).
These highly consistent lines of evidence affirm that 
dopamine plays an important role in the reward system.
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CHAPTER SIX
, AMPHETAMINE IMPACTS, REWARD
Introduction
It is now well accepted that amphetamine
administration can be neurotoxic to dopamine neurons. A
possible consequence of this toxicity is an alteration to
neural reward centers as dopamine is known to be an
important mediator of rewarded behavior. In addition,
researchers have compiled compelling evidence that has
implicated dopamine as a central substrate of reward
(Lippa, Antelman, Fisher & Canfield, 1973). Since
amphetamines are neurotoxic to the dopamine system, and
being that dopamine plays an important role in reward, it
is probable that amphetamine would impact reward mechanisms
in the brain.
In an effort to investigate the impact of amphetamine
on reward, researchers have conducted studies where they
pre-treat animals with amphetamine and then assess
rewarding effects of drugs using behavioral measures such
as drug self-administration and CPP. However, there have
been relatively few studies that have investigated the
impact of repeated amphetamine exposure on reward.
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Furthermore, the research that has examined the impact of
amphetamine exposure on reward has been controversial.
Some research indicates that amphetamines increase the
rewarding value of drugs of abuse while other studies
suggest that amphetamines decrease the rewarding value of
drugs of abuse.
Behavioral Research:
Evidence that Amphetamine
Impacts Reward
One study obtained results that support the theory
that prior exposure to amphetamine decreases the rewarding
value of drugs (Itzhak & Ali, 2002). Specifically, this
study examined the consequences of methamphetamine-induced
neurotoxicity on methamphetamine place preference. The
acquisition and reinstatement of methamphetamine-induced
CPP was measured in drug pretreated and saline pretreated
mice. Saline pretreated mice showed a much stronger
preference for the methamphetamine-paired room as compared
to the methamphetamine pretreated mice. Moreover, it took
longer to extinguish the conditioned response of the saline
pretreated group in comparison to the methamphetamine
group. In addition, the saline pretreated rats showed
stronger reinstatement of the place preference after a
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priming injection of methamphetamine. The results of this 
study suggest that pretreatment with a neurotoxic dose of
methamphetamine decreases the rewarding value of subsequent
methamphetamine exposure. The results of this study
support the theory that amphetamines decrease the rewarding
value of drugs of abuse.
A similar study to that of Itzhak and Ali (2002) was
conducted, but obtained results that support the theory
that amphetamine pre-exposure increases the rewarding value
of drugs (Gehrke, Harrod, Cass & Bardo, 2003). Rats were
pretreated with a neurotoxic regimen of methamphetamine or
saline, and were then conditioned 7 days later with
methamphetamine (0.1, 0.3, or 1.0 mg/kg, s.c.) or saline 
using a CPP procedure. Results indicated that a neurotoxic
dose of methamphetamine did alter subsequent
methamphetamine CPP. For saline controls, only rats that
received 1.0 mg/kg methamphetamine during conditioning
demonstrated CPP. In contrast, rats that received the
neurotoxic dose of methamphetamine demonstrated CPP when
administered either 0.3 or 1.0 mg/kg methamphetamine.
These results indicate that the rewarding effect of
methamphetamine was enhanced by neurotoxic doses of
methamphetamine.
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Another study lends further support to the theory that 
amphetamines increase the rewarding value of drugs (Lett, 
1989). Animals were divided into groups and pretreated
with either d-amphetamine or morphine. Animals were then
tested for either amphetamine-induced or morphine-induced
CPP. Results showed that repeated exposure to amphetamine
or morphine enhanced the drug-induced rewarding effects
measured by CPP. This study also showed that cross-drug
effects exist: exposure to amphetamine enhanced the
rewarding effect of morphine, and exposure to morphine
enhanced the rewarding effect of amphetamine. This cross­
drug effect is of particular importance because it suggests
that a common neural mechanism mediates the rewarding
effect of drugs with varying mechanisms of action. The
study suggests that with repeated exposure to drugs, the
probability of addiction increases because drug-taking
produces a progressively greater reinforcing effect each
time it occurs (Lett, 1989).
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The Dopamine D2 Receptor 
Hypothesis: The Role of 
the Dopamine D2 Receptor 
in the Ability of 
Amphetamine to Impact 
Reward
The neural mechanisms underlying the way in which
amphetamine impacts reward is not completely understood,
but it is hypothesized that dopamine D2 receptors play a key
role. Current research has shown that exposure to
amphetamine reduces the number of dopamine D2 receptor
binding sites (Bennett, Hollingsworth, Martin & Harp, 1998;
Chen, Su, Huang & Hsieh, 1999; McCabe, Hanson, Dawson,
Wamsley & Gibb, 1987; Volkow et al., 2001). Furthermore,
research has demonstrated that dopamine D2 receptor levels
are predictive of the rewarding properties of drugs of
abuse. Studies have shown that lower levels of D2 receptors
are associated with increased drug-liking, pleasure, and
euphoria (Laruelle, Abi-Dargham, van Dyck, Rosenblatt, Zea-
Ponce & Zoghbi, 1995; Volkow, Wang, Fowler, Logan, Gatley,
Gifford et al. 1999).
Evidence that Amphetamine 
Alters Dopamine D2 
Receptors
In one study, methamphetamine-induced reductions of D2
receptors in several areas of the rat central nervous
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system were measured (McCabe, Hanson, Dawson, Wamsley &
Gibb, 1987). Results showed a reduction in amount of
[3H]sulpiride binding sites in rat striatum after multiple
doses of methamphetamine. A significant reduction in
[3H]sulpiride binding was demonstrated in the striatum
(29.4%), nucleus accumbens (36.7%), and olfactory tubercle
(39.4%). Analysis indicated that the methamphetamine-
induced reduction in [3H]sulpiride binding to D2 receptor
sites was due to changes in number of receptors rather than
affinity. These results suggest that receptor changes may
be attributed to amount of dopamine released;
methamphetamine releases amounts of dopamine that would
result in a down-regulation of dopamine receptors. In
another study, the effect of methamphetamine exposure on
dopamine D2 receptor binding in cultured midbrain dopamine
neurons was examined (Bennett, Hollingsworth, Martin &
Harp, 1998) . Pretreatment with methamphetamine was found
to decrease the Bmax for [3H] raclopride binding, suggesting
that methamphetamine causes a down-regulation of dopamine D2
receptors. Additionally, following examination of D2 
receptor binding in rat striatum treated with amphetamine,
it was found that the Bmax value of D2 receptors in the
striatum decreased 40% on day 7 and 52% on day 10 after
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amphetamine withdrawal, without changes in their binding
affinities (Kd) (Chen, Su, Huang and Hsieh, 1999) . The
findings demonstrate that amphetamine administration for a
period of 14 days leads to diminished D2 receptor binding in
the striatum at late withdrawal periods.
Research linking amphetamine to decreased dopamine D2
receptor sites was extended by measuring levels of dopamine
D2 receptors in human methamphetamine abusers (Volkow et
al., 2001). Fifteen methamphetamine abusers and 20
nondrug-abusing comparison subjects were studied using
positron emission tomography (PET) to assess availability
of dopamine D2 receptors. Results indicated that
methamphetamine abusers had a significantly lower level of
D2 receptor availability than comparison subjects (a
difference of 16% in the caudate and 10% in the putamen).
The results of these studies suggest that amphetamine,
in addition to causing changes in presynaptic dopamine
markers, also reduce postsynaptic dopamine D2 receptors. It
was hypothesized that lower levels of D2 receptors in
amphetamine-treated subjects reflect receptor down­
regulation from exposure to a higher extracellular dopamine
concentration (Chen et al., 1998). The down-regulation of
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D2 receptors might reflect cellular mechanisms possibly
associated with amphetamine-induced neurotoxicity
Dopamine D2 Receptor Levels 
Predict Reinforcing
Response to Drugs
Treatment with amphetamine results in a reduction in
number of dopamine D2 receptor binding sites. This finding
is important, since studies have also demonstrated a
relationship between drug addiction and number of dopamine
D2 receptors (Laruelle et al., 1995; Volkow et al., 1999).
Specifically, these studies have found that number of
dopamine D2 receptors was predictive of the rewarding
properties of psychostimulants.
In one study, the relationship between the behavioral
effects of d-amphetamine and dopamine D2 receptor levels was
examined (Laruelle et al., 1995). SPECT imaging was used
to measure dopamine D2 receptor levels. Human subjects were
injected with d-amphetamine, and the behavioral effects of
the drug were measured by self-rating on the following
analog scales: euphoria, alertness, restlessness and
anxiety. Results showed that d-amphetamine injection
induced a decrease in D2 receptor availability. The d-
amphetamine injection induced marked increase in euphoria,
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alertness and restlessness scores. The intensity of these
behavioral responses correlated with the decrease in D2
availability measured with SPECT. In contrast, the anxiety
response was milder and not correlated with decrease in D2
availability.
In another study, PET was used to determine if there
were differences in striatal dopamine D2 receptor levels
between those human subjects who reported the effects of
methylphenidate as pleasant and those who reported them as
unpleasant (Volkow et al., 1999). The study also assessed
whether dopamine D2 receptor levels predict behavioral
responses to methylphenidate. Results indicated that
subjects who liked the effects of methylphenidate had
significantly lower dopamine D2 receptor levels than
subjects who disliked its effects. Moreover, the higher
the dopamine D2 levels found, the more intense were
methylphenidate's unpleasant effects.
The results of these studies provide evidence that
dopamine D2 receptor levels predict response to
psychostimulants in humans. Additionally, these results
suggest that low levels of dopamine D2 receptors may
contribute to psychostimulant abuse by increasing
pleasurable effects of drugs. Studies using human subjects
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support the same conclusions as those using animal
subjects: dopamine D2 receptor levels mediate reinforcing
responses to drugs of abuse. However, while studies using
human subjects have shown- dopamine D2 receptor levels to
increase the reinforcing response to drugs, animal studies
have shown dopamine D2 receptor levels to decrease the
reinforcing response to drugs. This is evidenced by the
decrease in the reinforcing effects of alcohol and morphine
in mice that lack dopamine D2 receptors (Maldonado, Saiardi,
Valverde, Samad, Roques & Borrelli, 1997; Phillips, Brown,
Burkhart-Kasch, Wenger, Kelly & Rubinstein, 1998), and by
the decrease in the reinforcing effects of cocaine in
animals given drugs to block dopamine D2 receptors (DeWit &
Wise, 1977; Spealman, 1990).
Conclusion
Research has demonstrated that amphetamines impact
reward. While the neural mechanisms underlying the way in
which amphetamine impacts reward is not clearly understood,
it is hypothesized that the dopamine D2 receptor plays a
role in the ability of amphetamines to affect the reward
system. Amphetamine administration reduces number of
dopamine D2. receptors. -Moreover, number of dopamine D2
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receptors is predictive of the rewarding properties of 
psychostimulants. Specifically, lower levels of dopamine D2 
receptor sites are associated with increased drug reward.
However, research is needed to examine the role of D2
receptor in the ability of amphetamine to impact reward.
This research will expand our knowledge of the neurobiology
of drug addiction and,may help us understand why some
individuals are more predisposed to abuse drugs than
others.
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CHAPTER SEVEN
EARLY AMPHETAMINE EXPOSURE
AFFECTS REWARD AND LATER
BEHAVIOR
Early Amphetamine Exposure 
Affects Reward
There are very few studies that have directly
investigated the impact of early amphetamine exposure on
reward. The studies that have been done in this area have
been exclusive to methylphenidate. This research has
looked at the effect of early methylphenidate exposure on
vulnerability towards drug abuse (Achat-Mendes, Anderson &
Itzhak, 2003; Anderson, Arvanitogiannis, Pliakas, LeBlanc &
Carlezon, 2001; Brandon, Marinelli, Baker & White, 2001).
Some studies suggest that early methylphenidate exposure 
decreases later vulnerability towards drug abuse while 
other studies suggest early methylphenidate exposure
increases later vulnerability toward drug abuse.
One study obtained results that support the theory
that early methylphenidate exposure decreases later
vulnerability towards drug abuse (Anderson et al., 2001).
In this study, rats were given intraperitoneal injections 
of methylphenidate (2.0 mg/kg) or saline twice daily on PND
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20 to PND 35. This period approximates pre-adolescence in
humans. At PND 60, CPP was used to assess the rewarding
effects of cocaine. Rats pretreated with saline during
development showed dose-related increases in the amount of
time spent in the environment associated with cocaine. In
contrast, methylphenidate pretreated rats spent less time
in environments associated with a moderate dose of cocaine.
A higher dose of cocaine that established place preference
in saline pretreated rats failed to establish place
preferences in methylphenidate pretreated rats. The
results of this study suggest methylphenidate exposure in
developing rats decreases responsiveness to the rewarding
effects of cocaine. The findings suggest that early
exposure to methylphenidate makes drugs of abuse less
rewarding later in life.
In contrast, another study obtained results suggesting
that early methylphenidate exposure increases vulnerability
towards drug abuse (Brandon et al., 2001). Adolescent rats
were pretreated with either methylphenidate (2 mg/kg for 7
days) or saline on PND 35 to PND 42. In adulthood, the
reinforcing effects of cocaine were measured using drug
self-administration. It was found that adolescent rats
pretreated with methylphenidate self-administered cocaine
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in adulthood at a higher rate compared to rats pretreated
with saline. It was concluded that adolescent exposure to
low doses of methylphenidate may increase vulnerability to
the reinforcing effects of cocaine. These findings support
the theory that early methylphenidate exposure increases
vulnerability towards drug abuse by increasing the
rewarding value of drugs.
In another study that looked at the effect of
adolescent methylphenidate exposure on drug reward,
adolescent mice received intraperitoneal injections of
methylphenidate (10 mg/kg) or saline on PND 26 to PND 32
(Achat-Mendes et al., 2003). In adulthood, induction and
reinstatement of cocaine-induced CPP was assessed.
Methylphenidate pretreatment during adolescence resulted in
a reduced preference for the cocaine-paired compartment in
adulthood as compared to the saline pretreated animals.
However, 2 weeks following extinction of cocaine-induced
CPP and withdrawal from cocaine, a priming injection of
cocaine was given. The priming injection of cocaine
reinstated significantly higher CPP in the methylphenidate
group than the saline group. The findings suggest that 
exposing mice to methylphenidate during adolescence
ultimately increases cocaine-induced reward in adulthood.
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This increased reward was observed particularly after a 2-
week withdrawal period from cocaine. It is suggested that 
exposure to methylphenidate in adolescence may cause
enduring neural adaptations that impact the reward system
in adulthood, causing a heightened propensity for drug
relapse (Achat-Mendes et al., 2003). Methylphenidate may
trigger long-lasting neural adaptations that are expressed
as an increased sensitivity to a cocaine challenge
following withdrawal from cocaine. This is believed to be
relevant to vulnerability to drug relapse (Achat-Mendes et
al., 2003).
Early Amphetamine Exposure 
Affects Later Behavior
Although there are few studies that have directly
investigated the effect of early amphetamine exposure on
reward, there have been several studies that have examined
the effect of early amphetamine exposure on other
behavioral measures. While developing rats appear to be
resistant to the neurotoxic effects of amphetamine,
behavioral deficits following amphetamine exposure have
been observed. Rats pretreated with methamphetamine during
the preweanling period (PND 1-20) exhibit an augmented
acoustic startle response, reduced locomotor activity, and
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impaired performance in a complex multiple-T water maze
(Vorhees, Ahrens, Acuff-Smith, Schilling & Fisher, 1994).
Multiple-T mazes are considered to be tests of reference
memory and appear to involve processes such as vector
navigation using proximal cues (Etienne, 1992). Therefore,
it appears that methamphetamine-pretreated preweanling rats
have long-term deficits in memory processes that depend on
stable cues and on determining spatial position based on
time and direction of movement (Vorhees et al., 1994). In
addition, methamphetamine pretreatment during the
preweanling period results in adult learning deficits that
are specific to spatial navigation and memory (Vorhees,
Inman-Wood, Morford, Broening, Fukumara & Moran, 2000).
Furthermore, methamphetamine pretreatment during the
preweanling period induces selective impairment of
reference memory-based spatial learning while sparing
sequential cued, and working memory-based learning
(Williams, Morford, Wood, Wallace, Fukumura, Broening &
Vorhees, 2003). Taken together, this research suggests
that the effects of methamphetamine exposure during the
preweanling period are both long-lasting and stage
dependent, impacting arousal as well as cognitive
functions.
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CHAPTER EIGHT
SUMMARY AND HYPOTHESIS
ADHD is the most common neuropsychiatric diagnosis in
children. It is estimated that 3%-5% of children meet the
diagnostic criteria for ADHD (Palfrey, Levine, Walker &
Sullivan, 1985) . Methylphenidate currently remains the
single most effective way to treat ADHD. In addition, the
clinical use of methylphenidate for 3- to 6- year old
preschool children who meet the diagnostic criteria for
ADHD is becoming more common. However, little is known
about long-term effects of methylphenidate on the very
young. Given the increasing number of young children being
treated with methylphenidate, much more research is needed
to compare the safety and efficacy of stimulant medication
across development. It is important to consider the
possibility of adverse effects of stimulant medication on
the developing brain. One major concern is whether early
methylphenidate treatment would alter the brain in such a
way as to impact the rewarding■value of drugs, thereby
increasing later vulnerability towards drug abuse.
Amphetamines are known to be neurotoxic to the
dopamine system, and dopamine systems play a critical role
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in mediating the rewarding effects- of drugs. Research has
shown that amphetamine exposure can impact drug reward.
However the results of this research have been
controversial, as some research indicates that amphetamine
exposure increases the rewarding value of drugs while other
studies suggest amphetamine exposure decreases the
rewarding value of drugs. The neural mechanisms by which
amphetamines impact reward is not completely understood,
but it is hypothesized that the dopamine D2 receptor plays a
key role. Repeated-exposure to. amphetamine reduces the
number of dopamine D2 receptor binding' sites (Bennett et
al., 1998; Chen et al., 1999; McCabe et al., 1987; Volkow
et. al., 2001). Current research has demonstrated that
dopamine D2 receptor levels are predictive of the rewarding
properties of drugs (Volkow et al. 1999). Studies have
shown that lower levels of D2 receptors are associated with
reports of increased drug-liking, pleasure, and euphoria
(Laruelle et al. 1995).
Since methylphenidate is an amphetamine, the question
remains as to whether repeated methylphenidate exposure,
like other amphetamines, decreases dopamine D2 receptor
levels and impacts drug reward. It is possible that
methylphenidate treatment during development may decrease
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dopamine binding sites and thus increase later
vulnerability towards drug abuse. A recent study found
that dopamine D2 receptor levels in the striatum declined as
a function of methylphenidate therapy in patients with ADHD
(Ilgin, Senol, Gucuyener, Gokcora, Atavci & Sener, 2001).
Research examining the effects of early
methylphenidate exposure on vulnerability towards drug
abuse is sparse, and the findings have been inconclusive.
Some studies suggest that early methylphenidate exposure
decreases later vulnerability towards drug abuse while
other studies suggest early methylphenidate exposure
increases later vulnerability toward drug abuse.
Furthermore, there has not been any research that has
examined the effect of methylphenidate exposure during the
preweanling period on later vulnerability towards drug
abuse. Research is needed to investigate the possible
adverse consequences following methylphenidate treatment
during the preweanling period. . Of particular interest is
the question of whether early methylphenidate treatment
would increase later vulnerability towards drugs of abuse.
Therefore, for my thesis, I propose to determine
whether treatment with methylphenidate during the
preweanling period will alter the rewarding properties of
80
morphine in adult rats. To determine whether morphine is
rewarding, I will use a CPP paradigm. In this paradigm, a
rat is given morphine, and it is restricted to a particular
compartment of the CPP apparatus. On alternating days, the
rat is given saline, and it is restricted to a different
compartment. The compartments of the CPP apparatus have
distinctive colors and odors.
In the proposed study, I will investigate the effects
of early methylphenidate exposure on the acquisition,
extinction, and reinstatement of morphine-induced CPP. I
predict that rats given early methylphenidate exposure will
(1) spend a greater amount of time in the morphine-paired
environment than the saline exposed rats, (2) that the
morphine-induced place preference will be harder to
extinguish in the methylphenidate pretreated rats than the
saline pretreated rats, and (3) that the morphine-induced
place preference will be more readily reinstated in the
methylphenidate pretreated rats than the saline pretreated
rats. In investigating the extinction and reinstatement of
morphine-induced CPP, I will be able to determine the
consequences of early methylphenidate exposure on morphine
withdrawal and relapse. I propose that methylphenidate
exposure during development-causes long-lasting neural
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alterations that have the potential to impact not only
vulnerability towards drug abuse, but also, vulnerability
towards drug relapse. Should the results of my experiment
support my hypotheses, it will have implications for the
clinical use of methylphenidate in young children diagnosed
with ADHD.
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CHAPTER NINE
METHODS
Subjects
Subjects were 83 male and female rats of Sprague-
Dawley decent, born and raised at California State
University, San Bernardino. Rats were kept with the dam
until weaning, when they were placed into group cages with
same-sex littermates. No more than one rat from each
litter was placed into a particular group. The colony room
was maintained at 21-23°C and kept under a 12-hour
light/dark cycle.
Drugs
Methylphenidate hydrochloride was dissolved in saline 
and injected intraperitoneally (ip) at a volume of 5 ml/kg 
Morphine sulfate was also dissolved in saline and injected
subcutaneously (sc) at a volume of 1 ml/kg. Both drugs 
were purchased from Sigma Aldrich (St. Louis, MO).
In Vivo Drug Treatment
Starting at postnatal day (PND) 10, rats received
daily injections of saline or methylphenidate (2 or 5
mg/kg, ip, 5 ml/kg). These daily injections continued for
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10 consecutive days (this age span is analogous to early
childhood in humans).
Conditioned Place 
Preference Apparatus
Conditioning and testing were done in a T-shaped
chamber consisting of three compartments. The two large
end compartments are adjacent to each other and separated
by a removable partition. The two end compartments measure
24 x 30 x 45 cm. The small compartment (the placement
chamber) projected out from the junction between the large
compartments. The small compartment measured 24 x 10 x 45
cm. A second removable partition enabled rats to enter
either of the large compartments from the placement
chamber. The odor, flooring, and color of each compartment
varied. One of the large end compartments had white walls,
wire mesh flooring, and pine bedding. The other large
compartment had black walls, metal rod flooring, and cedar 
bedding. The placement chamber had a solid wood floor and
was painted gray.
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Conditioned Place 
Preference Procedure
Preconditioning Day
On Day 1, following acclimation to handling, a total
of 83 (n = 6 per group) 60-day-old rats were put into the
placement chamber of the apparatus. After rats entered
either the black or white compartment, access to the
placement chamber was blocked, and rats were allowed 15 min
of free access to both large end compartments. Preferences
for the black and white compartments were determined for
each rat at the end of the day. No injections were given on
the preconditioning day.
Conditioning Phase
There were 8 daily conditioning sessions (Days 2-9)
lasting 30 min each. On each conditioning day, rats either
(a) received an injection of morphine (1 or 5 mg/kg, sc, 1
ml/kg) and placed in their non-preferred compartment, or
(b) received an injection of saline and placed in their
preferred compartment. Injections of morphine and saline
were alternated daily, and the initial drug order was
counterbalanced between groups.
85
Test for Induction of 
Morphine-Induced
Conditioned Place 
Preference
On the test day (Day 10), rats were put in the
placement chamber, and given free access to the large end 
compartments for 15 min. The CPP procedure was videotaped,
and time spent in each compartment was scored by
experimenters who were blind to treatment conditions.
Induction of CPP was determined by comparing total time
spent in the non-preferred compartment with total time
spent in the preferred compartment on Induction Test Day.
Similar to the preconditioning day, rats received no
injections on the test day.
Extinction Phase
For 8 consecutive days (Days 11-18), all rats were
given daily injections of saline. Each rat underwent 4
saline sessions in the previously drug-paired compartment
and 4 saline sessions in the previously saline-paired
compartment. Placement in the previously drug-paired
compartment and previously saline-paired compartment were
alternated daily.
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Test for Extinction of 
Morphine-Induced
Conditioned Place 
Preference
On Day 19, a test for extinction was performed
following the same procedure used in the testing for
induction of CPP. Rats were put in the placement chamber,
and given free access to the large end compartments for 15
min. Extinction of CPP was determined by comparing total
time spent in the drug-paired compartment with total time
spent in the saline-paired compartment on Extinction Test
Day.
Test for Reinstatement 
of Morphine-Induced 
Conditioned Place 
Preference
On Day 20, rats received a priming injection (1 mg/kg)
of morphine. Fifteen min later, rats were allowed free
access to the two compartments for 30 min. The time spent
in each compartment was recorded. Reinstatement of CPP was
determined by comparing total time spent in the drug-paired
compartment with total time spent in the saline-paired
compartment on Reinstatement Test Day.
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Experimental Design and 
Statistical Analysis
The study was a 2 x 3 x 2 experimental design. Sex had
2 levels: male or female. Drug pretreatment had 3 levels:
0, 2, or 5 mg/kg methylphenidate. Drug treatment had 2
levels: 1 or 5 mg/kg morphine. Litter effects were
controlled by treating litter as a random factor in all
analyses.
Body Weight
Preweanling weights during the 10 days of
methylphenidate drug administration were analyzed using a
2 (sex) x 3 (pretreatment) x 10 (day) between-subjects 
ANOVA. Adult weights on the 1st day of CPP testing were 
analyzed using a 2 (sex) x 3 (pretreatment) between-
subjects ANOVA. Tukey tests were used as a post hoc
analysis to determine the differences between the 3
pretreatment groups.
Preconditioning Compartment
Preference
Preconditioning room preference was analyzed using a
3(pretreatment) x (compartment). within-subjects ANOVA that 
compared total time spent in the black compartment with 
total time spent in the white compartment.
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Induction of Conditioned 
Place Preference
Induction of CPP was analyzed using a 3(pretreatment)
x (post treatment) within-subjects ANOVA that compared
total time spent in the drug-paired compartment with total
time spent in the saline-paired compartment for each rat.
Extinction of Conditioned 
Place Preference
Extinction of CPP was analyzed using a 2 (sex) x 3
(pretreatment) x 2 (post treatment) between-subjects ANOVA
that compared total time spent in the drug-paired
compartment with total time spent in the saline-paired
compartment between the different treatment groups. Tukey
tests were used as a post hoc analysis to determine the
differences between the 3 pretreatment groups.
Reinstatement of 
Conditioned Place 
Preference
Reinstatement of CPP was analyzed using a 2 (sex) x 3
(pretreatment) x 2 (post treatment) between-subjects ANOVA
that compared total time spent in the drug-paired
compartment with total time spent in the saline-paired
compartment between the different treatment groups.
Reinstatement was analyzed in 3 time blocks: 1st 15 min, 2nd 
15 min and 30 min. Tukey tests were used as a post hoc
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analysis to determine the differences between the 3
pretreatment groups.
Locomotor Activity on the
First and Last Day of 
Morphine Exposure
Locomotor activity on day 1 and day 8 of conditioning
was analyzed using separate 2 (sex) x 3 (pretreatment) x 2
(post treatment) between-subjects ANOVA. A 2 (sex) x 3
(pretreatment) x 2 (post treatment) x 2 (day) repeated
measures analysis was also done to compare 'locomotor 
activity between the first and last day of drug exposure
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CHAPTER TEN
RESULTS
Preweanling Body Weights
Preweanling body weights were not differentially
affected by methylphenidate pretreatment nor did they 
differ by sex. There was a significant, increase in body 
weight from the first day of injections (PND 10) to the 
last day of injections (PND 19) with rats weighing
significantly more with each additional day (see Figure 1) 
(Day main effect, F(9,216)=1984.47, p < .01, Tukey tests).
Adult Body Weights
At PND 61, males weighed significantly more than
females regardless of drug pretreatment (Sex main effect,
F( 1,24)=362.04, p < .01). Interestingly, rats treated with
5 mg/kg methylphenidate were significantly heavier than
rats treated with saline or 2 mg/kg methylphenidate.
Further analyses, however, showed that this effect was only
apparent in females (see Figure 2) (Sex x Pretreatment
interaction, F(2,24)=3.81, p < .05, Tukey tests).
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Rats were injected with methylphenidate (0, 2, or 5 mg/kg) 
from PND 10 to PND 19. Body weight was not differentially 
affected by methylphenidate pretreatment.
Figure 1. Mean Preweanling Body Weights During 10 Days of 
Methylphenidate Injections
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Adult Weights
400'
I Males 
Females
a Indicates a significant difference between male and female 
rats.
b Indicates a significant difference in female rats
pretreated with 0 mg/kg methylphenidate.
Figure 2. Mean Body Weights (+ SEM) on the First Day of 
Conditioned Place Preference Training (PND 61) 
for Male and Female Rats Previously Exposed to 
Methylphenidate (0, 2, or 5 mg/kg) from PND 10 to 
PND 19
Initial Chamber Preference
Regardless of drug pretreatment, rats showed an
initial preference for the black compartment over the white
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compartment (see Figure 3) (Room main effect,'
F(16,40)=2.19, p < .05).
Initial Preference Day
Black White
Compartment
Rats were previously exposed to methylphenidate (0, 2, or 5 
mg/kg) from PND 10 to PND 19.
a Indicates a significant difference from time spent in the 
white compartment.
Figure 3. Mean Time Spent in Each Compartment (± SEM) on 
the Initial Preference Day (PND 60)
Induction of Conditioned 
Place Preference
Rats given either 1 mg/kg or 5 mg/kg morphine 
demonstrated induction of CPP, because rats spent more time
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in the drug-paired room as compared to the saline-paired 
room (see Figure 4) (Room main effect, F(l,17)=5.01, p <
.05). No significant sex or pretreatment effects were
found.
Acquisition Test Day 
700-i-----------------------------------------------------
600-
co
Drug-Paired Saline-Paired
Compartment
Rats were given alternating daily injections of morphine (1 
or 5 mg/kg) and saline on PND 61 to PND 68. Data for the 
drug-paired compartments were collapsed across the two 
doses of morphine.
a Indicates a significant difference from time spent in the 
saline-paired compartment.
Figure 4.. Mean Time Spent in Each Compartment (± SEM) on 
the Induction Test Day (PND 68)
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Extinction of Conditioned 
Place Preference
Methylphenidate pretreatment increased the time needed 
to extinguish CPP, as rats treated with 5 mg/kg 
methylphenidate were slower to extinguish than rats treated
with the low dose of methylphenidate or saline
(Pretreatment main effect, F(2,3)=812.93, p < .01, Tukey
tests). Morphine dose also affected rate of CPP
extinction, because rats treated with 1 mg/kg morphine were
slower to extinguish than rats treated with 5 mg/kg
morphine (Post treatment main effect, F(l,3)=731.32, p <
.01). However, the ability of the high dose
methylphenidate pretreatment (5 mg/kg) and the low dose 
morphine conditioning treatment (1 mg/kg) to increase time 
spent in the drug-paired room during extinction testing was
only significant for female rats (see Figure 5) (Sex x
Pretreatment x Post treatment interaction, F(2,3)=237.84, p
< .01, Tukey tests). Overall, CPP was harder to extinguish
in male rats (M=196.629 S, SEM=44.484) than in female rats
(M=180.804 S, SEM=39.140) (Sex main effect, F(l, 3)=33.68, p
< .05) .
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Reinstatement of 
Conditioned Place
Preference
During the first 15 min block on the reinstatement 
test day, CPP was more readily reinstated in rats 
pretreated with 5 mg/kg methylphenidate than rats 
pretreated with 2 mg/kg methylphenidate or saline
(Pretreatment main effect, F(2,16)=9.57, p < .01, Tukey
tests). In addition, there was a significant post
treatment effect such that CPP was more readily reinstated
in rats treated with 5 mg/kg morphine than rats treated
with 1 mg/kg morphine (Post treatment main effect,
F(l,16)=7.11, p < .05) (see Figure 6). There were no
significant effects found in the second 15 min block of
time. For the entire 30 min block of time, CPP was more
easily reinstated in rats pretreated with 5 mg/kg
methylphenidate (M=1051.778 S, SEM=65.356) than rats 
pretreated with 2 mg/kg methylphenidate (M=747.000 S,
SE=78.351) or saline (M=890.621 S, SEM=81.186)
(Pretreatment main effect, F(2,16)=4.29, p < .05, Tukey
tests). There were no significant sex effects found during
reinstatement.
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1 mg/kg Morphine 
15 mg/kg Morphine
Methylphenidate Pretreatment (mg/kg)
During extinction training (PND 69-PND 76), rats were 
injected with saline and given alternating daily placements 
in the black and white compartments.
a Indicates a significant difference from rats pretreated 
with 2 mg/kg methylphenidate or 0 mg/kg.
b Indicates a significant difference from rats treated with 
5 mg/kg morphine.
Figure 5. Mean Time (± SEM) Spent in the Drug-paired
Compartment on the Extinction Test Day (PND 77)
98
800'
Reinstatement Test Day
1 mg/kg Morphine 
5 mg/kg Morphine
0 2 5
Methylphenidate Pretreatment (mg/kg)
All rats were primed with a 1 mg/kg dose of morphine 15 min 
prior to testing.
a Indicates a significant difference from rats pretreated 
with 2 mg/kg methylphenidate or 0 mg/kg.
b Indicates a significant main effect from rats treated with 
1 mg/kg morphine.
Figure 6. Mean Time (± SEM) Spent in the Drug-paired 
Compartment on the Reinstatement Test 
Day (PND 78)
Locomotor Activity
On the first day of morphine administration, rats
treated with 1 mg/kg morphine displayed more locomotor
activity than rats treated with 5 mg/kg morphine (Post
treatment main effect, F(l,3)=18.28, p < .05). Locomotor
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activity did not differ between drug groups on the last day
of morphine administration. Locomotor activity for rats
treated with 5 mg/kg morphine increased significantly from
the first drug exposure to the last drug exposure (see
Figure 7) (Post treatment x Day interaction, F(l,3)=16.24,
p < .05). This sensitization effect was not found for rats
treated with 1 mg/kg morphine. Neither methylphenidate
pretreatment or sex affected locomotor activity of rats
during the CPP procedure.
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Locomotor Activity
150-
1 mg/kg Morphine 
5 mg/kg Morphine
Exposure Day
During conditioning, rats were injected with either 1 or 
5 mg/kg morphine.
a Indicates a significant difference from rats treated 
with 5 mg/kg morphine on Day 1.
b Indicates a significant difference from rats treated 
with 5 mg/kg morphine on Day 8.
Figure 7. 'Mean Line Crosses (± SEM) on the First and Last
Days of Conditioned Place Preference Conditioning
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CHAPTER ELEVEN
DISCUSSION
Effects of Preweanling 
Methylphenidate Exposure on
Morphine-Induced Reward 
in Early Adulthood
Methylphenidate pretreatment has been found to
significantly alter the rewarding properties of drugs in
rats (Achat-Mendes et al., 2003; Anderson et al., 2002;
Brandon et al., 2001). In the present study, it was found
that methylphenidate exposure during the preweanling period
affects morphine-induced CPP. Three original predictions
were made regarding the effect of methylphenidate
pretreatment on morphine-induced CPP. Specifically, it was
hypothesized that: (1) rats given early methylphenidate
exposure would spend a greater amount of time in the
morphine-paired environment than saline-exposed rats; (2)
the morphine-induced place preference would be harder to
extinguish in methylphenidate-pretreated rats than saline-
pretreated rats; and (3) the morphine-induced place
preference would be more readily reinstated in
methylphenidate-pretreated rats than saline-pretreated
rats. The prediction that rats pretreated with
methylphenidate would spend a greater amount of time in the
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morphine-paired environment was not supported, because the 
induction of CPP did not differ among the methylphenidate 
pretreatment groups. It was also predicted that morphine- 
induced place preference would be slower to extinguish in 
methylphenidate-pretreated rats than saline-pretreated 
rats. This hypothesis was supported. Rats pretreated with 
the high dose of methylphenidate were slower to extinguish
than rats pretreated with the low dose of methylphenidate
or saline. Lastly, it was predicted that morphine-induced
place preference would be more readily reinstated in 
methylphenidate-pretreated rats than saline-pretreated 
rats. This hypothesis was supported during the first 15
min block of time, because CPP was more readily reinstated
in rats pretreated with the high dose of methylphenidate
than rats pretreated with the low dose of methylphenidate
or saline. The present results indicate that preweanling
methylphenidate exposure has a long-term impact on the
rewarding properties of morphine. Specifically,
preweanling methylphenidate administration appears to
increase the rewarding value of morphine. Past research
supports the notion that early methylphenidate exposure 
impacts drug reward (Achat-Mendes et al., 2003; Anderson et
al., 2002; Brandon et al., 2001). However, none of the
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prior studies administered methylphenidate during the
preweanling period. Rather, methylphenidate was
administered during the pre-adolescent and adolescent
stages of development. The reports examining the effects
of adolescent methylphenidate exposure on drug reward are
inconclusive (Achat-Mendes et al., 2003). For example,
pretreating 4-week-old rats with methylphenidate (2 mg/kg)
caused an increase in cocaine self-administration two weeks
after methylphenidate treatment (Brandon et al., 2001). In
contrast, pretreating rats with methylphenidate (2 mg/kg)
on PND 20-35 reduced the rewarding effects of cocaine on
PND 60 (Anderson et al., 2002).
Methylphenidate may impact drug reward differently
depending on the developmental stage at which it is
administered. Interestingly, exposure to methylphenidate
during the adolescent period appears to increase drug
responsiveness, while exposure during the earlier pre­
adolescent period reduces responsiveness to later
psychostimulant administration (Anderson et al., 2002;
Brandon et al., 2001). The developmental stage at which
methamphetamine is administered also impacts long-term
neurotoxic effects, with developing rats failing to exhibit
the characteristic pattern of long-term methamphetamine
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neurotoxicity (Cappon et al., 1997). Therefore, it would
not be surprising if the developmental stage during which 
amphetamines, such as methylphenidate, are administered has
a differential effect on drug reward.
Body weight measurements provide additional evidence
that methylphenidate's effects vary according to age. When
administered on PND 10 - PND 20, methylphenidate and saline
did not differentially affect body weight (See Figure. 1) .,
Not only did methylphenidate not inhibit weight gain during
the preweanling period but on the first day of CPP testing
(PND 61), females pretreated with the higher dose (5 mg/kg)
of methylphenidate weighed more than females pretreated
with the lower dose of methylphenidate (2 mg/kg) or saline.
While this finding contradicts research showing that
methylphenidate inhibits weight gain (Spencer et al., 1996;
Vincent, Varley & Legger, 1990), most of these studies have
administered methylphenidate during later stages of
development. This indicates that there may be
developmental differences in the way methylphenidate
impacts body weight.
The results revealed a methylphenidate dose effect,
with the higher dose of methylphenidate (5 mg/kg) causing
an increase in the rewarding value of morphine. Rats
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pretreated with the high dose of methylphenidate (5 mg/kg)
were slower to extinguish as compared to rats pretreated
with the low dose of methylphenidate (2 mg/kg). Similarly,
CPP was more readily reinstated in rats pretreated with the
high dose of methylphenidate than rats pretreated with the
low dose. In fact, the low dose of methylphenidate had no
effect on reward at ail. This suggests that higher doses
Of methylphenidate are more likely to alter reward
mechanisms in preweanling brain. However, rats pretreated
with 2 mg/kg methylphenidate during adolescence
self-administered cocaine at a higher rate than rats
pretreated with saline (Brandon et al., 2001). This
suggests that a low dose of methylphenidate does impact
reward during later stages of development. It should be
noted that while 5 mg/kg is considered a high therapeutic
dose, young children are often prescribed a higher doses of
methylphenidate than adolescents and adults (Volkow et al.,
2001).
One of the major differences between the present study
and previous studies is that all other studies assessed 
methylphenidate's impact on the rewarding properties of
cocaine, while we examined morphine CPP. This has
particular significance when discussing the role of the
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mesolimbic dopamine system in reward. It is generally
acknowledged that dopamine receptors in the mesolimbic 
system mediate reward (Ikemoto & Panksepp, 1999). Drugs of
abuse share the ability to selectively stimulate dopamine
release within the mesolimbic system (Ikemoto & Panksepp,
1999). Methylphenidate causes long-lasting neural
alterations to the mesolimbic dopamine system, thereby
impacting the rewarding properties of cocaine (Achat-Mendes
et al., 2003; Anderson et al, 2002; Brandon et al., 2001).
By demonstrating that methylphenidate exposure can also
impact the rewarding properties of morphine, we provide
further evidence that the mesolimbic dopamine system
mediates reward. And more importantly, this provides
further evidence that methylphenidate exposure causes
neural alterations to the mesolimbic dopamine system.
The neural mechanisms underlying amphetamine's ability
to alter the mesolimbic dopamine system and impact reward
are not completely understood. But I have hypothesized
that dopamine D2 receptors play a key role. Exposure to
amphetamine reduces the number of dopamine D2 receptor
binding sites (Bennett et al., 1998; Chen et al., 1999;
McCabe et al., 1987; Volkow et al., 2001). Furthermore,
dopamine D2 receptor levels are predictive of the rewarding
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properties of drugs of abuse. Lower levels of D2 receptors
are associated with increased drug-liking, pleasure, and
euphoria (Laruelle et al., 1995; Volkow et al., 1999).
Thus, it is possible that methylphenidate, like other
amphetamines, decreases the number of dopamine D2 receptor
binding sites, with this effect being greatest at higher
doses. This reduction in dopamine D2 receptor binding sites
may be responsible for an increase in the rewarding
properties of drugs of abuse following methylphenidate
exposure.
In the present study, methylphenidate impacted the
extinction and reinstatement of morphine-induced CPP while
not affecting induction. Interestingly, similar results
were obtained when mice were pretreated with
methylphenidate (10 mg/kg) from PND 26-32 and tested for
the induction and reinstatement of cocaine-induced CPP
(Achat-Mendes et al., 2003). While pre-exposure to
methylphenidate initially impaired the acquisition of
cocaine-induced CPP in adulthood, reinstatement of cocaine-
induced CPP was greater in mice pretreated with
methylphenidate. Taken together, these results suggest
that methylphenidate-induced neural adaptations in the
reward system are slow to develop. Ultimately, both
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studies suggest that early methylphenidate exposure results
in an enhanced response to the rewarding • effects of drugs.
Implications for Use of 
Methylphenidate for the
Treatment of Attention-Deficit/
Hyperactivity Disorder in
Early Childhood with Regard ' 
to Vulnerability Towards •-
Drug Abuse
The present study indicates that preweanling
methylphenidate exposure increases the rewarding properties
of drugs of abuse. It has been found that methylphenidate
exposure during the preweanling period causes enduring
changes in the neurobiology of brain reward systems,
thereby impacting drug reward. The preweanling period in
rats is analogous to early childhood in humans. Therefore,
our findings have implications for use of methylphenidate
for the treatment of ADHD in early childhood. The age at
which stimulant treatment is given seems to be an important
factor, presumably because of the way it impacts the
maturation of the dopamine system (Robbins, 2002). During
early childhood, the brain dopamine system is still
maturing (Solanto, 1998). Therefore, stimulant medication,
such as methylphenidate, may affect the brain of a young
child differently than the brain of an adolescent or adult.
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Our findings suggest that preweanling methylphenidate 
exposure does impact the reward system, since it was found 
that methylphenidate administration increases the rewarding 
value of drugs of abuse. These findings imply that 
stimulant treatment during early childhood may act as a
risk factor for drug-seeking and drug-taking in adulthood.
Thus, one may be more susceptible to drug addiction because
drugs of abuse become more rewarding following stimulant
treatment in early childhood.
Our study found methylphenidate to impact extinction
and reinstatement of morphine-induced CPP. The
extinction/reinstatement paradigm is often used as a model
of relapse (Fuchs et al., 1998). By using an
extinction/reinstatement paradigm in the study, we were
able to investigate the consequences of early
methylphenidate exposure on morphine withdrawal and
relapse. Our findings suggest that methylphenidate
exposure during early childhood not only increases
vulnerability towards drug abuse, but also increases
vulnerability towards drug relapse. This suggests that the
neural alterations triggered by methylphenidate exposure
during early childhood are long-lasting and may potentially
persist for many years.
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Animal research assessing the effects of preweanling
methylphenidate exposure on vulnerability towards drug
abuse is sparse. Further research is needed to ascertain
how neuroadaptations caused by stimulant exposure are
affected by dose, age at exposure, and treatment duration
(Anderson et al., 2001). In addition, further molecular
work is needed to ascertain which neural substrates are
responsible for methylphenidate's impact on drug reward,
with special attention given to measuring dopamine D2
receptor levels. Given the findings of this study, it is
important to consider the possibility of adverse effects of
stimulant medication on the developing brain. There is a
lack of research within the human population assessing the
use of stimulant medication for preschool-aged children.
This is particularly important because preschool-aged
children diagnosed with ADHD may be treated with stimulants
for many years (Connor, 2002). Our study suggests that
particular attention should be given to further
investigating the possibility that stimulant treatment
during early childhood increases one's vulnerability 
towards drug abuse. It is hoped that additional clinical
research will examine the balance between the short-term
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expediency of methylphenidate treatment and the longer-term 
risk of promoting future drug abuse (Robbins, 2002).
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